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ABSTRACT OF THE DISSERTATION
CERVICAL INFECTION WITH HIGH-RISK HUMAN PAPILLOMAVIRUS
ANOGENITAL SUBTYPES IN INDIGENOUS WOMEN IN
ALTA AND BAJA VERA PAZ, GUATEMALA
by
Anne Jeffries
Florida International University, 2018
Miami, Florida
Professor Consuelo Beck-Sagué, Major Professor
Cervical cancer, caused by oncogenic (high risk [hr]) human papillomavirus (HPV)
subtypes, is the most common cancer in women in Guatemala and the most common
cause of cancer mortality in women aged 15-44 years. Visual inspection with acetic acid
(VIA) with onsite cryotherapy “test-and-treat” is recommended for underserved
Guatemalan indigenous rural women. This research assessed: 1) hrHPV infection
prevalence in women screened by VIA; 2) Sensitivity and specificity of VIA in detecting
hrHPV infection and cytologically identified precancerous and cancerous lesions; and 3)
Factors associated with hrHPV infection. Analysis of anonymous data collected during
VIA clinics in 2013 (N = 205) and 2017 (N = 234) for indigenous women aged 21-65
years in six villages showed 22.6% (95% confidence interval [CI]=18.7%-27.2%) had
hrHPV cervical infection. VIA results were abnormal in 5.9% (95%CI=3.8%-8.8%).
Only nine VIA exams in 89 women with hrHPV were abnormal (Sensitivity=10.1%,
95%CI=4.7%-18.3%), although abnormal VIA was associated with hrHPV (Prevalence

vii

Ratio [PR])=1.8; 95%CI=1.1-3.1; P=.05). Of 221 women who had VIA, hrHPV nucleic
acid testing and liquid preparation cytology (equivalent to Papanicolaou or “Pap”)
testing, 10 (4.7% [95%CI=2.3%-8.5%]) had abnormal cytological results, including one
cancer, four high- and five low-grade squamous intraepithelial lesions. VIA sensitivity
and specificity for detection of precancerous cytological abnormalities and cancerous
lesions were 20.0% (95%CI=2.5%-55.6%) and 96.0% (95%CI=92.3%-98.3%)
respectively. In contrast, hrHPV sensitivity and specificity were 100% (95%CI=71.7%100%) and 88.7% (95%CI: 83.9%-92.7%). In both years combined, women aged fewer
than 29 years or reporting fewer than four pregnancies were more likely to have hrHPV
cervical infection (36.8%, 27.3%, respectively) than those who were older or reported
more pregnancies (18.7; <.0001 and 17.9%; P=.025, respectively); 60.0% reported some
form of modern contraception. Progesterone injections or implant users were more likely
to have hrHPV infection (31.9%) than women using other or no contraceptives (19.5%);
PR=1.6; 95%CI=1.1-2.4; P=.01). These data suggest that VIA may not be sufficiently
sensitive for use in cervical cancer screening. “Test-and-treat” screening using hrHPV
real-time testing, as recommended by the World Health Organization may be preferable
to VIA, and may be acceptable using self-collected specimens.
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I. INTRODUCTION
Background
Cervical cancer is one of the most studied and best-understood malignancies.
Cancer producing (“high-risk” or oncogenic) human papillomavirus (hr-HPV) subtypes
are recovered in 95%-100% of cervical cancer specimens and hrHPV infection has been
identified as a necessary element in most cases of cervical carcinoma1-11. Although
cervical cancer is one of the most preventable and treatable cancers, it remains a leading
cause of cancer mortality in women worldwide2,4,6-9,12-16. In high-income countries,
cervical cancer morbidity and mortality have dramatically declined due to the use of
cytological screening with Papanicolaou (pap) “smears” and timely treatment. Cervical
cancer screening with cytology has been considered standard-of-care for decades; at least
75% of women participate in cervical cancer screening in high-income countries15. At
present, 81%-87% of new cervical cancer cases and deaths are believed to occur in lowand middle-income countries (LMICs)2,4-9,12-16, in which women have limited access to
needed screening. Guatemalan indigenous women are at particular risk for cervical
cancer due to their marginalization, yet there is no registry for indigenous people and
cancer rates in Guatemalan indigenous people, who represent greater than 50% of the
population17.
Statement of the Problem
The Latin American and Caribbean (LAC) region is home to just nine percent of
the world population, but bears approximately 16% of the world burden of cervical
cancer mortality18,19. Lack of infrastructure to provide care, including screening and
follow-up, and poverty, creating marginalized populations in low-income countries,
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perpetuate barriers to health care access. According to a 2011 Pan-American Health
Organization (PAHO) report “by the year 2030, cervical cancer is expected to kill over
474,000 per year, 95% of these deaths in low-and middle income countries20”, an
apparent result of low access to screening, diagnosis and effective treatment. Guatemala
is a middle-income country plagued by inadequate healthcare infrastructure, endeavoring
to provide service to remote indigenous populations. In LMICs, a highly promoted
strategy for low-cost cervical cancer screening is visualization and inspection with acetic
acid (VIA). VIA is often performed as part of cervical examination with magnification
using colposcopy. In LMICs, it is used in conjunction with immediate treatment with
cryotherapy in a “see-and-treat” exam. Colposcopy uses magnification for biopsy and
curettage of tissue within the cervical os. The biopsies and endocervical tissue from the
curettage are examined for cellular changes. The results of the tissue histopathology
guide treatment decisions. In contrast, VIA relies exclusively on examiner’s naked-eye
assessment, so training is vital. The judgment to treat is based on the unmagnified exam,
with no laboratory validation. Cryotherapy as a treatment for precancerous lesions is not
entirely without risk, but generally is well tolerated. Initial side effects can include watery
discharge, pelvic pain, vaginal bleeding and potentially infection. Risks include infection,
obliteration of the cervical transformation zone and stenosis of the cervical os,
complicating future evaluations. The benefit of immediate treatment may be outweighed
by the difficulty in establishing continuity of care, and follow-up over years, an essential
component that has decreased mortality in high resource countries.
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Significance of the Study
Little is known of the prevalence of high-risk HPV subtype infection in rural
indigenous women in Guatemala21. or the effectiveness of low-cost screening techniques,
such as VIA, currently used to identify women with precancerous and cancerous
lesions22-24. However, there is growing concern about the acceptability and efficacy of
VIA in Guatemala, due to country-specific training and competence issues and issues
related to VIA itself24.
Current Study Aims
The objectives of this research are to:
1. Estimate the prevalence of high-risk anogenital HPV-subtype cervical
infection in Alta Vera Paz, rural Guatemala;
2. Evaluate the sensitivity and specificity of VIA in detection of clinically
significant cervical infection with high-risk anogenital HPV-subtypes using as
the gold standard nucleic acid high-risk subtype-specific HPV testing and
liquid-based cytology (equivalent to Papanicolaou or “Pap smears”);
3. Identify factors associated with hrHPV infection in the indigenous female
population in the Alta and Baja Vera Paz regions of Guatemala.
The overarching goal of this research is to evaluate the gaps between screening
and effective treatment of precancerous and cancerous lesions in rural Guatemala,
interventions to eliminate those gaps and efforts to reduce the substantial preventable
HPV-associated mortality in the region. Evaluation of VIA requires simultaneous
collection of samples HPV DNA hybrid testing, cytology and or biopsy, and the
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laboratory technology to conduct these tests. Lack of laboratory availability is already
identified in Guatemala as a deficit, and the healthcare infrastructure has no method for
follow-up24 or patient tracking. Therefore there has been little opportunity to validate the
results of VIA in rural Guatemala and determine if the exam is likely to reduce the
mortality associated with cervical cancer.
Hypotheses: Based on literature review and preliminary studies, we hypothesized that:
1. High-risk HPV-subtype cervical infection prevalence in the study population will
exceed 20%.
2. “Real world” sensitivity of VIA to detect active infection with high-risk HPV
subtypes will be lower than published estimates of 30%-40%.
3. Cervical cancer screening in rural Guatemala with HPV testing would be
improved by hrHPV testing with onsite same-visit (“real-time”) results.
This research compared VIA results to hrHPV and state-of-the-art cytological
testing and assessed the prevalence of hrHPV infection in the Vera Paz regions in
Guatemala. Analysis of de-identified data collected during VIA clinics during which
hrHPV testing was performed allowed assessment of hrHPV prevalence, and estimation
of sensitivity and specificity of VIA screening vs. hrHPV testing and cytological
evaluation. This study assessed prevalence in the Vera Paz region of Guatemala. Previous
to this research, a study by Valles25 et al in 2009 in Escuintla, Guatemala, showed high
hrHPV prevalence.
A secondary analysis of data collected to compare VIA with cytology and hrHPV
screening assessed the sensitivity and specificity of VIA during free VIA clinics in rural
communities in the Vera Paz regions of Guatemala. There have been no previous studies
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of this kind assessing VIA in the field in rural Guatemala indigenous persons outside of
urban settings.
The referral of patients to specialized diagnostic and treatment facilities is
informal, and is reliant on patient initiative and adherence. Chary26, 2015 published her
study following women within INCAN (Instituto Nacional de Cancerología [National
Institute of Cancer] the National Cancer Hospital in Guatemala City), as they navigated
their way through the system for care. Rural indigenous women have identifiable barriers
to general and particularly specialized care including travel time and cost, loss of work
and care of family during absence; this unique community has cultural perspectives and
historical relationships with the non-indigenous population that must be considered. Even
once in care, equipment and medications are often unavailable, broken or too expensive.
Memory of Silence, a document mandated by the Peace Accords in 1994, was
completed by the Commission for Historical Clarification, an impartial record, obtained
through survivor testimony, of the human rights abuses perpetrated upon the Mayan
people and communities over the three decades of civil conflict in Guatemala27. The
document describes the military dictatorship’s agenda of instilling fear of the government
and exerting control of Mayan communities through use of torture, rape and
disappearances, sometimes forcing indigenous persons to perform these acts against other
community members. Loss of the communities and culture is evident today in the
decreased use of traditional dress, an external declaration of ethnicity. The Justice system
lost credibility as it ignored human rights violations inflicted on civilians by the
Guatemalan military.
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The deep shortage of resources and opportunity in Guatemalan rural indigenous
communities reflects worldwide historical and contemporary inequities28. Discrimination
toward the indigenous people and poor access to preventive health care are compounded
by the gender inequality and violence experienced by indigenous women29 which are
associated with increased risk for cervical cancer30.
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II: LITERATURE REVIEW
Theoretical Foundation: Theory of Gender and Power
The theories that inform this analysis are the Theory of Gender and Power1
(Figure 1) and the Theory of Planned Behavior (Figure 2)1. Women in Guatemala have
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long been subject to male dominance, and to a lack of women’s health infrastructure and
contraception services2. The Theory of Gender and Power examines a woman’s capacity
on three levels. The first (Division of Labor), in Guatemala strongly favors men. Income
inequality is related to education inequity2,3 only 39.9% of rural indigenous women are
literate and of those, nearly 80% have attended school an average of three years3,4 while
53.3% of rural indigenous men are literate3. Guatemalan women bear most of the
responsibility in raising children and Guatemala has one of the highest fertility rates in
Latin America and the Caribbean (LAC) (Figure 3)5. Total fertility rate is directly and
Figure 3. Cervical cancer incidence and mortality, by total fertility rate, 23 selected
countries, Americas Global Initiative for Cancer Registry Development, 2012, and Total
Fertility Rate, WHO.

strongly significantly associated with cervical cancer incidence (p = .0075) and cervical
cancer mortality (p=.0079).
Childbearing and childcare responsibilities also limit their access to employment
and higher parity is associated with increased risk for cervical cancer6,7. Poverty is a
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recognized risk factor for cervical cancer8,9, and nearly 71% of the rural population of
Guatemala lives in poverty8.A majority of indigenous women work in home farming, a
primary source of food and income, yet only 26% farm family-owned land – and that is
generally owned with their husband10. Farming and care of animals and wood gathering
are primarily women’s responsibility, not income generating. It is estimated that women
contribute four-fold what men contribute in domestic work3, 86% of households rely on
wood as fuel, which contributes to the degradation of natural resources, perpetuating the
poverty cycle. Wood burning for cooking exposes the women to smoke, which is
suspected of not only promoting respiratory illness but also increasing risk of cancers10.
The Sexual Division of Power in the theory is manifested by the violence against
women in Guatemala. The death rate resulting from violence against women in
Guatemala, the third highest in Latin America in 201211-13, perpetuates a vulnerable
female society. The Guatemala Human Rights Commission has investigated the roots of
this violence, with the civil war contributing a component11. Indigenous women suffered
extreme violence at the hands of the government forces12-14. During the civil war, rape
and torture were used to terrorize the indigenous population13-16. Contemporary research
indicates organized crime and gang activity also perpetrate violence against women2,
perpetuating misogynistic attitudes. These are exacerbated by government indifference in
prosecuting these crimes2,11,12 continuing the cycle. It is estimated that partner
violence2,11,12 is an important cause of femicide (gender-based homicide). Domestic
violence was the suspected cause of 61% of the femicides in Guatemala in 200811.
Perpetrators of violence against women have enjoyed impunity, with less than 2% of
cases involving violent deaths of women prosecuted between 2005 and 20072,11,12. Child
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abduction and forced prostitution of girls and women also contributes to the violence
against women and increased risk of cervical cancer2,16,17.
The Theory of Gender and Power offers a core interpretation of relationships
within a culture based on the sociopolitical concept of gender, as distorted by combined
forces of government-endorsed, extrajudicial and criminal violence1,17,18 (Figure 1). This
structure controls opportunities afforded to women, and their subjugation within
communities that are themselves are intensely subjugated. Community structures
establish social norms and religious beliefs that serve to control relationships within
patriarchal frameworks1. The restrictions of working within the home to support the
family, and selling produce in the local markets limit women’s economic power. Lack of
health care access and negative societal concepts regarding contraception (religious
prohibitions, and understanding of contraception as a form of government population
control in the context of genocidal efforts) may be constraining forces on women’s
personal fertility control and autonomy. Infrastructure deficits in health care access
constitute an institutional discrimination, accepting indifference to women. Unprosecuted
femicide tacitly communicates the appropriateness of violence towards women, and
misogynistic paradigms isolate women from justice and political power. Indigenous
people have struggled to gain respect and trust the government following the civil war,
but there is deep-seated mistrust of governmental services14,15, both judicial and servicerelated, that isolates indigenous women from self-realization. Women in Guatemala have
multiple challenges in seeking health care: poverty, isolation, disrespect of their ethnoidentification and deficient social programs to promote literacy and economic security8.
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Theory of Planned Behavior
The Theory of Planned Behavior (Figure 2) explains issues related to women’s
ability to learn about and incorporate cervical cancer screening into their lives, and how
the community of women at risk accepts pelvic exam, and understands and acknowledges
personal risk. The Theory of Planned Behavior1,19,20 is an extension of the Theory of
Reasoned Action21 and posits that intentions predict behaviors, that is, intentions are
predicted by attitudes toward the behavior and subjective norms about the performance of
the behavior, and extends the Theory of Reasoned Action to include perceived behavioral
control. Specifically, the Theory of Planned Behavior suggests that intentions are
predicted by attitudes toward the behavior and subjective norms about the performance of
the behavior22. The Theory of Planned Behavior suggests that, provided support for their
health care seeking, and educational efforts to encourage self-protection, if not selfrealization, women can change the subjective community norm.
Low levels of control may politically and economically increase indigenous
Guatemalan women’s risk not only for physical violence but also for conditions like
reduced access to cervical cancer screening, diagnosis and effective treatment23.
Understanding the communities, power structure, and health behaviors related to access
and education can open the dialogue to health literacy, but the overwhelming poverty
must be addressed to provide greater autonomy to the people and women in particular.
Paul Farmer writes “…inequities have powerfully sculpted not only the distribution of
infectious diseases, but also the course of disease in those affected”23. Writing about
emerging infectious diseases, his statements apply to cervical cancer, recently recognized
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to be a chronic infection, “An implication, clearly, is that one place for disease to hide is
among poor people, especially when the poor are socially and medically segregated”23.
This certainly typifies the situation in Guatemala, where death from cervical cancer is not
recorded in vital records24,25 and the actual toll on women is extrapolated, not determined.
Reliance on health promoters from within indigenous communities provides a construct
through which women can begin to understand the concept of screening for cervical
cancer, and normalizes pelvic exams26. As rural indigenous women are educated to
understand the risk of cervical cancer, they can accept and promote screening, as access
is made available through the NGOs offering care. This, in the lens of the Theory of
Planned Behavior, evolves into intention to seek care through improved access, and
community acceptance of the exam, facilitating for the health care seeking behavior.
Cervical cancer is a daunting burden on both social and economic sectors of
Guatemala. Control of cervical cancer in Latin America has been for the most part
unsuccessful9,27. Herrero et al.28 estimate that even if incidence rates are not increased,
there would be an increase in case numbers solely based on the population aging. The
screening programs that have curtailed cervical cancer deaths in high-income countries
involve technical procedures, laboratory access, and consistent follow-up generally
regarded as too complex and expensive for poor communities countries like Guatemala
indigenous populations8. Nevertheless, the success of antiretroviral scale-up in low- and
middle-income countries worldwide, with plunging HIV-related mortality rates,
particularly in LAC, have sparked interest in offering technically complex interventions
in these countries, particularly to cancer patients29-32. Pursuit of technically advanced but
highly acceptable women’s health care and cervical cancer prevention and treatment in
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Guatemala should be pursued, within the context of the experience of the indigenous
women. Attentiveness to their need to have an understanding of the process respectfully
provided in their language, and with consideration of the historical and cultural gender
discrimination suffered, suggests that help must be sought from within the communities
to introduce the most effective interventions in the most acceptable way.
The Theory of Planned Behavior builds a base of education and local support for
women to structure an understandable and practical design for provision of their care. As
noted in rural Peru33 predictors for participation in screening programs included: knowing
a woman who had participated in VIA, having a supportive partner, having attended an
educational session concerning cervical cancer and having a satisfactory experience with
the health care system. Deterrents to participation included having a partner who does not
condone the exam, a poor experience interacting with the health care system, and belief
the exam was detrimental to her.
The lack of control politically and economically2, 34 increases indigenous
Guatemalan women’s risk for not only for physical violence but also for reduced access
to cervical cancer screening, diagnosis and effective treatment. Understanding the
communities, the power structure, and health behaviors related to access and education
can open the dialogue to health literacy, but the overwhelming poverty and unacceptably
low access to care must be addressed18,36-37.
Natural History of Human Papillomavirus (HPV) Infection
There is an abundance of literature describing the natural history of HPV since
even before the association/presence of HPV was noted in cervical cancers, when
screening techniques such as the Papanicolaou cytology (“pap smear”) and diagnostic
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approaches (e.g., biopsies under colposcopy) first suggested the sexually transmitted
nature of cervical cancer38,39. The current understanding of the natural history of HPV
further informs the protocols used in screening. The Bethesda terminology38 classifies the
lowest level of high-risk hrHPV subtype infection detectable by cytology (microscopic
assessment of samples obtained by pap or liquid preparation) as the squamous
intraepithelial lesion (SIL), low or high-grade, and describes the progression of lesions to
carcinoma in situ, defined as malignancy before metastasis (malignant spread) (Table 1).
Table 1 2014 Bethesda System for Reporting Results of Cervical Cytological
Examination
NILN
Squamous Cell:
NILN: Negative for intraepithelial lesion
ASC-US - Atypical squamous cell undetermined
significance, reported with hrHPV +/ASC-H - Atypical squamous cells, cannot exclude
high grade lesion
LSIL – Low grade intraepithelial lesion, mild
dysplasia/CIN 1
HSIL – High grade intraepithelial lesion.

SCC

Moderate/severe dysplasia/ CIN 2, 3
CIS – Carcinoma in situ
SCC – Squamous cell carcinoma
Glandular Cell:
Atypical - Endocervical cells – favor neoplastic,
glandular cells – favor neoplastic
Endocervical adenocarcinoma in situ
Adenocarcinoma- specified as endocervical,
endometrial, extrauterine.
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of squamous cell or endocervical adenocarcinoma type38. An initial cellular change,
atypia, is a diagnosis for which pathological determination of cause by HPV co-testing is
recommended and if positive, closer follow-up is appropriate. This grading of lesions
requires laboratory sophistication and technique rarely available to women in rural areas
in low- and middle-income countries (LMICs); in high-income countries, the grading and
location of the lesion dictates the treatment protocol39. LSIL is considered an acute
infection phase, often cleared by immunocompetent women, while HSIL represents a
chronic infection and cellular changes, precursor to cancer. Gavitt and Winer40 examined
serum antibodies along with vaginal/cervical HPV detection; their research supports a
reactivation of prior infection in older women rather than newly acquired infection. They
also found an association of viral detection with the menstrual cycle, suggesting potential
effects of menopause on reactivation of the virus41.
Over 100 subtypes of HPV exist, 40 of which are associated with the anogenital
tract41-49. “High risk” (hrHPV) subtypes, those that can cause malignancies, can establish
persistent infections, causing a disruption of the normal maturation of cells in the
epithelial layers by proliferation within the squamocolumnar junction (SCJ)40-44,50 (Figure
4). The SCJ, is also called the transformation zone, where epithelial cell transition occurs,
from resistant squamous cell epithelium (consisting of multiple layers of tough cells) to
the much more susceptible single-cell layer of columnar cells. Over 90%
of lower genital tract cancers arise in the SCJ (Figure 4)39,50. It is thought that the virus
enters basal cells below the columnar cells via micro-abrasions. As HPV infects the
cervical cells, it causes the host to replicate HPV. With the help of the host cells’ normal
shedding, more viral particles are released39-42. Once integrated into the host, these genes
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Figure 4. Coronal section diagram of cervix (A) and microscopy (B) from Herfs et al.
PNAS. 2012; 10516-21.

enter basal cells below the columnar cells via micro-abrasions. As HPV infects the
cervical cells, it causes the host to replicate HPV. With the help of the host cells’ normal
shedding, more viral particles are release39-42. Once integrated into the host, these genes
disrupt normal cells by binding to and inactivating tumor suppressor proteins39-42. Fifteen
HPV subtypes are classified as oncogenic; HPV 16 is thought to be present in nearly 50%
of cervical cancers and HPV 18 is responsible for an additional 10%-15%39-42,48,49.
Most women with normal cell-mediated immunity clear the active infection but the
infection can persist latently for decades42-46. The typically years-long natural history of
oncogenic HPV subtype infection in immunocompetent persons, and its typically slow
progression to malignancy, allows for intermittent screening. Generally, women aged
mid-thirties to fifties begin to exhibit cellular changes that progress to cancer. The
general population testing in Escuintla department in Guatemala by Valles25 in 2009
demonstrated an increase in hrHPV infection in women over 35 years of age. Such
changes are thought to be related to reactivation of the virus associated with changes
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related to menopause or immunity and even potential exposures by either new sexual
partners or long-term partners’ new sexual partners40. Cervical cancer is associated with
persistent infection, the course of which is influenced by viral genetics, host immune
response and related cofactors (e.g., HIV infection, malnutrition)42. Behavioral factors are
known to have the least influence with only a 1.5-2 fold increase in developing precancer after an infection with hrHPV Once integrated into the host, these genes disrupt
normal cells by binding to and inactivating tumor suppressor proteins39-42. Once
integrated into the host, these genes disrupt normal cells by binding to and inactivating
tumor suppressor proteins39-42. 52-58. Considering the modest impact of behavioral risk
factors, a woman’s risk of progression to cervical cancer is dependent upon not only her
behavior but that of her husband or partner’s.
The rapid acquisition of infection with an anogenital HPV subtype following
sexual debut59-62, 28.5% of women test positive for hrHPV subtypes within one year of
their sexual debut61, suggests that screening and treatment programs must address the
latency and potential reactivation of the infection. The reality is that most HPV infections
are spontaneously resolved39,43-45,63-65 and do not reactivate and progress to cervical
cancer, suggesting that overtreatment may occur if cytology and determination of the
degree of lesion to be treated are unavailable. The mere presence of hrHPV in the genital
tract does not in itself suggest inevitable progression to cancer for young
immunocompetent persons, which again points to the importance of infrastructure that
allows for follow-up, and laboratory sophistication to “grade” a lesion prior to
treatment35,64,65.
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Evaluation of Cervical Cancer Screening Tests
Screening is a process designed to detect disease processes before they become
symptomatic, and typically precedes a definitive diagnosis66. Screening tests reduce the
number of persons that must be tested to make a definitive diagnosis, generally by
identifying a population at higher or highest risk. Screening generally uses a highly
sensitive test to identify the sub-population most likely to have the disease process. A
more specific test to identify the “true” cases of the condition (“confirmatory” test) often
follows the screening tests. Screening tests are evaluated by what percent of persons with
a positive “gold standard” test they detect (test “sensitivity”) and “specificity” (the
percent of persons in whom a “gold standard” test has ruled out the condition that test
negative on the screening test). Sensitivity and specificity are test characteristics. The
predictive value of a positive or negative screening test is affected by the prevalence of
true positives in a population. The predictive value of a negative test (proportion of
negative screening tests that occur in persons that are truly negative) and predictive value
of a positive test (proportion of positive screening tests that occur in persons that are truly
positive) assess screening test performance at specific population levels. In populations
with very low prevalence of the condition for which persons are being screened, even
tests with very high specificity will have low positive predictive values.
Cervical Cancer Screening in Low Income and Middle Income Countries
To assess and address cervical cancer in underserved and low-resource
populations, VIA has been proposed28,64,65, 67-71. Hinselmann, who experimented with
VIA in 1924, first studied the cervix using acetic acid, which is known to whiten
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precancerous and cancerous lesions72. VIA developed into colposcopy when
magnification improved the technique. During colposcopy, biopsies of lesions are taken
for diagnosis and to “stage” lesions, determining disease progression, as Hinselmann’s
research demonstrated that visualization alone was not sufficient to diagnose
precancerous lesions or cervical cancer71. This technique is used to confirm pathology
and direct treatment as needed. Colposcopy became widespread in medical practice in the
1960s-70s. In the 1990s found many LMICs resorted to VIA as a screening technique,
revisiting historic development of screening approaches of cervical cancer. The minimal
need for equipment and immediate results were believed to meet the needs for screening
for low-resource settings. However the accuracy of VIA remains difficult to assess.
Denny et al.73 in 2002 compared VIA to VIA with magnification and cytology in
South Africa. There was minimal difference in sensitivity of direct visualization and
enhanced view with magnification. Both had negative predictive values of 94.4%-97.2%
in all lesion categories (high- or low-squamous intraepithelial lesion) as did cytology
(94.5%-96.5%). The positive predictive value of the cytological examination was 34.5%,
whereas VIA had a positive predictive value of 12.9%-13.7%. The subjectivity of the
test, improper application of acetic acid and poor visualization of the cervix were offered
as explanations for lesion detection failure in VIA. In 2005, Sarian, et al.74 as part of the
Latin American Screening study assessed the performance of VIA and against
colposcopy found a sensitivity of 45.4%-50% for HSIL. The study included hrHPV
testing, and in conclusion discussed augmenting VIA with hrHPV screening, following
up women testing positive with colposcopy. The authors advise that “there is no
argument that organized cytology screening is the only cost-effective means of cervical
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cancer control” pointing to the need to explore ways to improve access to cytology
screening within a context linkage of patients with suggestive results to specialized care.
In Peru, Jeronimo et al.69 in 2005 compared VIA to pap smear using colposcopy as the
gold standard, and determined positive predictive value of both VIA and pap smears to be
under 10%. It is noted that the providers performing the pap and VIA exams were
oncologists69. Yet in the discussion portion, the authors state “VIA…requires a low level
of training”69. The study does confirm the benefit of immediate results with VIA, noting
that 26.3% of women with abnormal pap were lost to follow-up in contrast to 2.3% of
women with an abnormal VIA. Herrero et al.28 examined screening methods in two Latin
American countries. In Costa Rica, liquid-based pap, conventional pap and HPV testing
were compared; liquid-based pap was shown to have sensitivity/specificity of
87.5%/87.8% compared to pap smear as the gold standard, and 63%/93.7% and HPV
testing at 85.3%/88.2%. All the tests had a >99% negative predictive value, with positive
predictive value of 11.5% for conventional pap, 8.5% for HPV testing and 9.0% for the
liquid-based pap. Costa Rica developed a National Cytology Laboratory during the
reorganization of the cervical cancer-screening program and since noted a decline in
incidence and mortality from cervical cancer. Costa Rica committed resources into
establishing infrastructure for diagnostics and treatment, which improved continuity of
care. In Peru, VIA had similar results: HPV testing was the most sensitive (89.7%)
however prevalence of abnormal cytology was noted to increase with age while hrHPV
positivity decreased. Examiners were trained midwives, and over the course of the study,
false positive VIA decreased with experience, demonstrating subjectivity in the exam,
need for practice, and little evidence of VIA being technically “extremely simple”. The
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study discussed cytology, hrHPV testing and VIA, and concluded that VIA was
appropriate where no other screening options were available but that any program of
screening must include referral for specialized care. The study in Peru was part of a
project to increase coverage of screening (TATI project75). An adjunct of the TATI study
by Alamonte76 was situated in a remote area of Peru, and found that the conditions under
which the testing occurred were more apt to reflect the usual conditions in which routine
screening was taking place. Both VIA and pap smears performed below expectations
compared to other studies; routine cytology (pap smear) was ineffective for screening due
to inadequate laboratory quality which also was reflected in the liquid-based cytology.
Cytology has been proven in high-income countries to be sufficient for screening, but
considerable investment in laboratory facilities and technician expertise must be made
before this screening option will be useful in LMICs. Costa Rica is an example of a
country where such investment has been made with promising results. Sherris71 in 2009
reviewed studies that compared VIA with cytology and colposcopy, noting that rural Peru
found a sensitivity of 26% for conventional cytology in the region, revealing the
unacceptable sensitivity of pap smear for screening in this setting. The Latin American
Screening77 study was conducted in Brazil and Argentina, also comparing VIA with
cytology in four cities (three in Brazil and one city in Argentina). Researchers found a
similar prevalence of hrHPV in the four cities ranging from 15.4% to 18.8%. There were
higher rates of insufficient sampling with the conventional pap compared to liquid-based
cytology, which would require a second visit to clinic to repeat the test. The authors
advise that “there is no argument that organized cytology screening is the only cost
effective means of cervical cancer control” pointing again to a failure of infrastructure. A
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meta-analysis by Sauvaget et al.78 in 2010 reviewed 26 VIA studies in which women had
confirmatory tests to determine the accuracy of VIA in screening, finding a sensitivity
ranging from 41%-92% (pooled sensitivity=80%). Specificity ranged from 49%-94%.
Only two of the studies were in Latin America. The studies that involved VIA compared
to colposcopy did not always confirm findings by histopathology, avoiding biopsies of
women with negative screening tests. In a study in Nigeria79, pap and VIA had
sensitivities of 60%, and specificities of 100% and 94.9%, respectively. In this study, the
risk of overtreatment was preferred over the risk of loss to follow-up, again considering
infrastructure as a necessary component in a successful screening program. In
Colombia80, mortality from cervical cancer was evaluated based on five variables:
women who reported yearly screening, women who did not receive results of cytology,
women with abnormal results who followed up for treatment, women who never had
cervical cytology and uninsured women. Increased screening coverage did not decrease
cervical cancer mortality in uninsured women. After adjusting for insurance coverage,
compliance with follow-up visits was associated with a 40% reduction in mortality.
Wright and Kuhn81 reviewed efforts in LMICs, finding that continuity of diagnosis and
treatment was the primary requirement in reducing mortality from cervical cancer and
avoiding overtreatment. Studies from India and South Africa reviewed by the authors
both indicated less disease progression in women screened and treated, if screened with
hrHPV. It was noted that in India there was no reduction in cervical cancer incidence or
mortality in the VIA and control arms of this prospective study81. A comparison of pap to
hrHPV testing to co-testing in the United States by Blatt et al.82 demonstrated that cotesting in high-income countries would improve diagnosis and treatment. In the results of

24

this study, 19% of women with cervical cancer would have been missed with hrHPV
testing alone. Pap (alone) sensitivity was 91.3%, hrHPV sensitivity alone was 94%, and
co-testing had a sensitivity of 98.8%. Utilizing cervical biopsy results, 14.4% of women
with abnormal pap had a negative hrHPV test, and of those with biopsies with an HSIL
result, 35.4% had cervical cancer. The women who were negative for hrHPV but had
high-grade lesions or cervical cancer were older, perhaps representing longer exposure,
lower tumor viral levels and underscoring the importance of screening older women at
risk for cervical cancer. In another meta-analysis of screening tests for cervical cancer in
sub-Saharan Africa, Fokom-Domgue et al.83 compared VIA with visual inspection with
Lugol’s iodine (VILI), a solution of potassium iodine, an iodine that turns cervical
precancerous and cancer lesions yellow) and HPV testing. Pooled sensitivity for VIA
was 82.4% and specificity was 87.4%. VILI sensitivity was higher than VIA and
specificity was similar. HPV testing demonstrated a pooled sensitivity of 88.3% and
specificity of 73.9%. The screeners preferred VILI, as the cervical mucosal changes were
more pronounced without needing reapplication of the iodine and there was no time lapse
before evaluation as there is with acetic acid. As with VIA, screening menopausal women
with VILI can be inaccurate as atrophied tissue does not take up the iodine. In 2015
Dawood and El-Tahmoudy84 also compared VIA, VILI and cytology, also demonstrating
similar sensitivities and specificities between VIA and VILI, with cytology
demonstrating lower sensitivity and higher specificity. Lack of access and follow-up was
again identified as a major deficit in cervical cancer control in LMICs. The meta-analysis
by Mustafa et al.85 also compared VIA, cytology and HPV testing, as well as
overtreatment compared to under-treatment. Consideration of the future consequences of
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over or under-treatment and the context of the woman being tested is an important
measure, along with actual mortality. Sensitivity and specificity are important but
outcomes have been difficult to measure in many LMICs. Zhou86 retrospectively
evaluated hrHPV test for precision in detecting high-grade cervical lesions as it has been
considered first line screening. The sensitivities were similar to prior studies at 80.8%
(hrHPV) and 81.2% (pap smear). False negative rates for hrHPV and pap were 8.7% and
9.1% respectively, with co-testing bringing the false negative rate to 1.2%. When
considering a screening test and the variables of fieldwork, the improvement in false
negative test was important. In Zhou’s study, 37% of the women with cervical cancer had
been hrHPV negative five years before. In 2017, Raifu87 evaluated VIA compared to
VILI and physicians to nurses as examiners. With both tests VIA and VILI, physician
sensitivity was higher than the nurses’ and sensitivity decreased with older participants,
an effect that has been observed in other studies. Positivity with hrHPV reduced
specificity yet improved both nurse and physician sensitivity, even though the result of
hrHPV test was unknown to the examiners. Looking at participant factors, Raifu
concluded that age, parity, and positive hrHPV increased the accuracy of the examiners.
This study indicated that the higher-grade lesion decreased the specificity of the hrHPV
screening test, and sensitivity decreased in the older woman screened with visual
techniques. Age (older, post-menopausal) and high parity have been identified in studies
as factors that increase a woman’s risk for cervical cancer7,88,89. Age risk is explained by
the natural history of hrHPV, the infection taking decades to reactivate, then progress to
cervical cancer. Screening menopausal women with VIA is less effective due to the
cervical tissue’s atrophic changes. As noted previously Guatemalan women have high
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fertility rates, a known factor to increased the risk for cervical cancer.
The difficulty in reviewing the accuracy of VIA includes the variations of disease
threshold, the standards used for comparison and failure to confirm negative VIA. There
can be discrepancies in experience and training of the VIA providers, ranging from
physicians with experience in colposcopy to a newly trained non-physician.
VIA does not allow for the grading of a lesion, unlike cytology, and cannot detect the
presence of hrHPV subtypes. Aceto-whitening of the cervix can be non-specific, with
reparative and immature squamous metaplasia also appearing white81. There is no
protocol for confirming negative VIA exams, the ability to screen for hrHPV subtypes
might enhance or even replace the VIA evaluation and provide better guidance for
follow-up for women unable to access the standard cytology screening recommendations.
Beyond studies that evaluate VIA in research settings, there has been little assessment in
actual use, where problems associated with non-standardization of training, turnover of
personnel, subjectivity and unavailable mentoring and continuing education potentially
affect the quality of the screening. These factors may reduce the ability of VIA in realworld situations to challenge the encouraging research data endorsing VIA alone as a
screening tool.
Treatment in Low and Middle Income Countries
In high-income countries, cervical cancer treatment has moved toward laser loop
electrosurgical excision procedure (LEEP), a treatment that uses a small electrical wire
loop to remove abnormal cells from the cervix, allowing for assessment of suspicious
lesions, grading of the extent of invasive changes and the evaluation of borders to verify
the complete removal of lesions90,91. High-income countries are actively eliminating
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overtreatment by not treating low-grade lesions, observing over time, and treating only
high-grade lesions. Cryotherapy – freezing the cervix with a probe to ablate the tissue,
allowing for growth of tissue without the infection – was formerly an accepted treatment.
It is no longer the treatment of choice in high-income countries due to the effects of
freezing on cervical tissue and inability to document complete excision of the lesion and
grade the extent of invasion. Cryotherapy causes ablation of the lesion, which may
precludes subsequent VIA exams due to scarring of the cervical tissue and the migration
of the transformation zone, where the SCJ lies and HPV infection proliferates, and
narrowing of the cervical os, which create difficulty in accessing the SCJ for adequate
sampling in later screening70,71,90. There is a theoretical risk of cervical insufficiency and
complications of pregnancy caused by disruption of cervical tissue. Maza90 discusses
quality of gas use in cryotherapy, comparing carbon dioxide (CO2) to nitrous oxide
(N2O). CO2 is often easier to obtain; however, impurities can cause inconsistent
temperatures and equipment malfunctions. Equipment requires sterilization between
women treated, and Maza notes that it is unpredictable in number of patients who can be
treated (2-20). Cryotherapy is indicated for treatment of precancerous lesions if
endocervical curettage is negative, biopsy confirms disease, invasive cancer is ruled out
and the complete lesion is visible. With VIA in LMICs, these treatment criteria may not
be well established.
Moreover, the ability to immediately treat with cryotherapy provides a false sense
of security, understating the need for continued follow-up and assessment. Schmidt et
al.91 followed a small group of women treated with cryotherapy and found there were
recurrences within 2 and 5 years, 24% of which were adenocarcinoma, which is more
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difficult to diagnose and in which HPV is not always detectable. Appropriate follow-up
with pap smear or biopsy must be incorporated into care, as recurrences should be
anticipated if no grading of lesions is done prior to cryotherapy.
The complications of cryotherapy are generally mild, but can include pain,
cramping, and watery discharge91-95. Women need to be prepared for this and for the
recommendation for abstinence from sexual intercourse until healed. Thus, treatment
with cryotherapy can contribute to both failure to pursue and difficulty in conducting
future screening with VIA due to the cervical changes caused by the freezing. The
cervical changes necessitate biopsy and a higher technical level of diagnostic capability
that these techniques are designed to avoid91-93. Several studies in Africa and Asia have
provided significant information regarding the use of VIA and “see and treat” programs
offering cryotherapy. In 2012, Ziyauddin and Rajyashiri93 in India compared cryotherapy
to LEEP. As previously noted LEEP requires electricity to perform, as well as costly
equipment and a high level of training. It had a cure rate of 94.4% and was useful for
diagnosis. In contrast, cryotherapy had a cure rate of 88.2% in this prospective study
following women for one year. Even in this relatively short-term study, participants were
lost to follow-up and four recurrences occurred in the cryotherapy treatment group of 34.
Continued surveillance of treated women is imperative to recognize recurrence, and is a
challenge that must be addressed with infrastructure. Cryotherapy is not indicated for
treatment of endocervical lesions or glandular disease, neither of which can be assessed
by VIA, but which can potentially be obscured by cryotherapy92. Failure of cryotherapy
can be caused by inadequate freezing of the tissue because of inadequate gas pressure for
delivery, poor probe application and insufficient time for freezing94,95. Assessment of
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impact of VIA and cryotherapy on cervical cancer in Guatemala is desperately needed.
Cryotherapy is not a definitive treatment for cervical cancer, but a treatment for
precancerous lesions; therefore, the women treated with cryotherapy as part of a “see and
treat” intervention need to be informed that continued surveillance is needed91-95.
Recurrence at any age is possible. The nature of the chronic infection and progression
requires follow-up and continued care, which requires an infrastructure not currently
available in rural communities in Guatemala.
The global research conducted to identify strategies to decrease mortality from
cervical cancer suggests that VIA is an acceptable screening tool, but the addition of
hrHPV co-testing offers improvement in both sensitivity and specificity in testing for risk
for cervical cancer and pre-cancerous lesions. No screening can be done in a vacuum;
infrastructure to follow-up as needed and to keep records regarding testing and treatment
is essential. Catarino et al.95 discuss the emerging technologies, as they have been trialed
and implemented in numerous LMICs, acknowledging that hrHPV may be negative in
the presence of a high-grade lesions, and recommend triage of women with positive
hrHPV tests. Valles26 in 2009 estimated that in Guatemala, pap smear coverage was less
than 10% of the vulnerable population. Winkler34 published a study on women’s
participation in cervical cancer screening in northern Peru and identified four predictors
of participation. These were: higher relative wealth; knowing women who have been
screened; knowledge and use of the health care system, and having a satisfactory
experience within the system34. This research supports the need for preventive health
education, and community endorsement of participation in screening. Accessing care is a
persistent barrier for poor Guatemalan women. The VIA mobile “brigades” have
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increased awareness of the risk for cervical cancer. Now, true follow-up for diagnosis and
treatment needs to be attainable. Self-sampling for HPV hybrid testing was studied in
with indigenous women residing in Santiago Atitlan96. Self-sampling, which does not
appear to reduce sensitivity, was found to be acceptable to the participants and all
indicated they would be willing to periodically provide a sample for testing. While this
greatly increases the simplicity of specimen collection, it still also requires a healthcare
system that can track patients for continuity of care.
Historical and Political Barriers
Guatemala has significant challenges in health care provision within the rural,
largely indigenous communities, with infrastructure deficits traceable through a historical
and political lens. Guatemala’s history since Spanish colonization is steeped in political
conflict and marginalization of the indigenous and rural populations, who suffered
economically and witnessed the dismantling of their social/community structures during
government-sponsored terrorism over the last three decades12-15. Prior to Spanish
colonization of the region, Guatemala’s population encompassed 30 separate culturally
and linguistically distinct subpopulations, most of which share the Mayan cultural
identification12,15,97. Survival of Guatemalan indigenous people was high, as evidenced by
the fact that they remain even after prolonged genocidal efforts, the majority of the
Guatemalan population (51%)12-15. Linguistically distinct Mayan communities existed
separately from the occupying structure, suffering loss of land, the primary source of
livelihood and sustenance12-15. In the late 1890’s the country’s economy became
internationalized through political negotiations with foreign companies, particularly the
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American United Fruit Company13,98. This company maintained significant influence and
power in the political arena, impacting all aspects of government activity in Guatemala98.
In the post-World War II era to mid-1950, there was a brief period of
representative elected government, labor reform and redistribution of lands to the rural
poor13,15, mostly descendants of the Mayan majority population. This era of reform was
brought to an end by a US CIA-backed military coup led by Guatemalan Army General
Carlos Castillo Armas2,13-15 because of concerns of possible Communist involvement in
the reforms. The military had long been, and again became, synonymous with the
government, suppressing any uprising, but also forcing governmental change through
military coups13-15. During the Armas tenure, 99.6%18 of the land that had been
nationalized and distributed to Mayans was returned to former landowners, including
international companies such as the United Fruit Company. The assassination of Armas
in 1957 plunged Guatemala into a violent civil war13-15,18 which devastated the indigenous
populations and rural poor and lasted over 30 years. The complete toll will never be
known but an estimated 200,000 people, were killed or “disappeared”, over 80% of who
were indigenous13-15,34. During this time, the government actively suppressed the
education of the Mayans and their economic stability. This coincided with government
maintenance of the status quo of poverty and illegalization of traditional Mayan healers99
exacerbating the marginalization and weakening of the culture12-15.
The Guatemalan Civil War, the longest and deadliest in Central America ended in
199612-15. The Comisión Nacional de Reconciliación (National Commission for
Reconciliation) took the first steps toward peace in 1989, but over seven years, fighting
continued until the accords that provided for the reconciliation between the armed forces
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and guerrilla groups34,35 and the forging of plans for social and infrastructure reparations
aimed at benefiting the poor, marginalized, rural, predominantly Mayan populations. Of
the over half of the population in Guatemala documented as indigenous12,15,97, 90% of the
population is classified as poor, or extremely poor12-15,34. The indigenous communities
endure much shorter life expectancy at birth (17 years shorter than non-indigenous
groups).34
At the time of the signing of the Peace Accords, the social security system
covered only 13% of the populations34,35,97,99 . This lack of infrastructure precluded the
government’s accomplishment of the health care improvement provisions of the Peace
Accords. Limitations of public health care expenditures were due to conditions of
international debt restructuring imposed by the World Bank and International Monetary
Fund35. The Ministry of Health (MOH) assigned the responsibility for rural health care to
NGOs, (an estimated 10,000-15,000) working in Guatemala99-102. The Programa de
Extensión de Cobertura (Program of Extension of Coverage, or PEC) was instituted in
1997 to improve healthcare access to the rural populations. PEC tried to contract with
NGOs already working in Guatemala, many of which declined participation to retain
autonomy35 and limit association with the MOH, a government agency that, due to the
long civil war, may have suffered from their association with the acts of the government
and by the historical mistrust of rural citizens. Even the philanthropic and religious
groups that had constituted the majority of NGOs in Guatemala present during the civil
unrest, working in response to natural disasters that plagued the country, tended to be
unwilling to accept MOH collaborations for similar reasons.
Since PEC had contracts and funds to distribute, and philanthropic and religious
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groups were unwilling to accept them, it turned to an entrepreneurial approach to health
care, funding newly contracted (including for-profit) NGOs with little or no experience in
rural health care delivery99-102. The MOH divided health care into curative and preventive
services but did not address infrastructure deficiencies and widespread poverty that
contributed to the failure of healthcare system initiatives15,34,99. In 2014, all contracts
between PEC and health care NGOs were cancelled in accordance with legislation
prohibiting the outsourcing of health care. This left a gap in care the country had no
immediate measures to replace103.
According to Instituto Catala d’Oncologia HPV Centre statistics published in
2017, cervical cancer was the leading cause of female cancer and of cancers deaths in
Guatemalan women aged 15-44, noting, however, that incidence in Guatemala is
extrapolated from surrounding countries24. As previously noted, Valles25 published a
study done in Escuintla, a first study in anogenital HPV infection prevalence in
Guatemala, comparing HPV in sex workers recruited from a sexually transmitted
infection (STI) clinic with general population HPV prevalence in women attending a
community clinic. He found prevalence rates of 38.1% within the general population, and
67.3% among sex workers. The prevalence of HPV for sex workers declined with age, a
trend not seen in the general population. Persistent infection has greater potential for
causing precancerous lesions; the authors had no explanation regarding the continued
high prevalence in the general population. The decline in prevalence with age was
generally noted across regions54 with a peak in the younger women as they become
sexually active. The persistence of HPV in middle-aged women precludes once-in-alifetime cervical cancer screening strategies. This study, though limited in numbers points
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to the chronic nature of infection and potential for cervical cancer to develop in later
decades.
A consistent theme throughout this review is the unmet need for optimal cervical
cancer screening. Yet this gap is also seen in access to treatment. Screening without
treatment is unethical104 and a waste of resources. Root cause analysis would focus on
access to screening, continuity of care and treatment. Social determinants of inequality
include many of the characteristics of the indigenous women in Guatemala: high rates of
poverty, lack of education, extreme gender bias and rural residency, among the factors
that make screening for cervical cancer difficult for Mayan women in Guatemala.
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Abstract
OBJECTIVE:
Determine prevalence of cervical infection with oncogenic (“high-risk” [hr]) human
papillomavirus (HPV) in indigenous women participating in two rural visual inspection
with acetic acid (VIA) campaigns in 2013 and 2017, and assess the sensitivity and
specificity of VIA in detecting hrHPV infection, and predictive values of normal and
abnormal VIA for hrHPV infection.
METHODS:
Analysis of anonymous data collected during VIA clinics in 2013 (N=205) and 2017
(N=234) for indigenous women aged 21-65 years in six villages in Guatemala from
whom specimens for hrHPV were collected at the time of VIA (total N=439).
RESULTS:
Of 393 with both VIA and hrHPV data, 89 (22.6%) had evidence of cervical hrHPV.
hrHPV prevalence varied by year (29.6% in 2013, 17.4% in 2017; P=.004). Of these 89,
37 were reported with specific subtypes, of which 26 (70.3%) were HPV16, 1 (2.7%) was
mixed HPV16/18, and 2 (5.4%) were HPV18. HPV16 was less common in 2013 (12/20
[60%]) than in 2017 (15/17 [88.2%]; P=.054). VIA was abnormal in only 10% of women
with positive hrHPV subtype infection (sensitivity); specificity was 95.4%. Predictive
values of positive and negative tests were 39.1% and 78.4%, respectively.
CONCLUSION:
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These data suggest that exclusive VIA use may not detect many women with persistent
infection and may be insufficient for screening. Real-time nucleic acid hrHPV detection
may be superior, coupled onsite treatment and an effective HPV immunization program.
Introduction
Cervical cancer is one of the most studied and best-understood malignancies.
Oncogenic (“high risk”) human papillomavirus (hrHPV) subtypes are recovered in 95%100% of cervical cancer specimens and have been established to cause most cases of
cervical carcinoma1-11. Though cervical cancer is one of the most preventable and
treatable cancers, it remains the fourth leading cause of cancer mortality in women
worldwide12. Industrialized countries have reduced cervical cancer mortality through
screening and over 80% of cervical cancer mortality currently occurs in low- and middleincome countries13-18. In 2010, cervical cancer was the fourteenth most frequent cause of
cancer in US women and the mortality rate was 2.4/100,00019.
In contrast, in low and middle-income countries, cervical cancer remains a
leading cause of death despite the existence of effective and modestly priced screening,
diagnosis and treatment. The Latin American and Caribbean regions are home to just nine
percent of the world population, but bear approximately 16% of the world burden of
cervical cancer mortality14,16,17,20,21. In Guatemala understanding hrHPV prevalence
cervical cancer incidence and related mortality is difficult due to the low resources
available to determine HPV prevalence and accurate data documenting incidence and
mortality7,8. As a result, these have been imputed from surrounding countries, and from
testing in specific areas.
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Considerable differences in economic status and access to health care, present
significant barriers to indigenous women in Guatemala. Over half (51%) of the
population in Guatemala is documented as indigenous22-24; 90% of indigenous persons
are classified as poor, or extremely poor23,24. Indigenous communities, particularly the
large Maya population, endure much shorter life expectancies, 17 years shorter than nonindigenous groups22-24 a consequence, of inaccessible health care, among many barriers
for this population. Health expenditures in 2014 were 2.3347% of GDP in Guatemala25,
limiting health service expansion. In rural areas, there is a system for primary care
consisting of 1,101 health posts employing a nurse, with varying access to mobile teams
consisting of a physician, a nurse, and volunteers at the community level called “health
facilitators” and “health guardians”26-29.
To assess and address needs related to cervical cancer in underserved Guatemalan
rural indigenous populations, visual inspection with acetic acid (VIA) has been proposed
as it has in many underserved settings9,31-35. However, little is known of the prevalence of
hrHPV oncogenic subtype infection in Guatemalan rural indigenous women, or
effectiveness of VIA in identifying women with lesions suspicious for hrHPV , onsite
“test-and-treat” strategies, and methods currently used to link them to specialized
care7,8,33. To explore the prevalence of hrHPV subtype infection and the effectiveness of
VIA in detecting hrHPV infection in this population, we analyzed anonymized data from
women who were screened as part of a nonprofit organization’s efforts to provide
services to this population.
Methods
VIA Screening Clinics
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The VIA screening clinics took place in two weeks in 2013 and 2017,
respectively, in six villages, two of which were visited twice. These villages were located
in Baja Vera Paz, immediately north of the capital region, and Alta Vera Paz, just north
of Baja Vera Paz (Figure 5). The villages included Rabinal and Campur (each visited in
both 2013 and 2017), Cahabon and Santa Cruz, visited just in 2013, and Carchar and
Tactic, visited in 2017 only. The VIA screening clinics were supported by two NGOs that
partner to bring services to rural Guatemala (Partners for Surgery and Timmy Global
Health in 2013 and Partners for Surgery 2017). The schedule of the VIA clinic was
coordinated with the local communities arranging for space to provide the clinic. The
schedule and availability of screening was announced by Promotoras de Salud (female
Community Health Promoters) employed by Partners for Surgery, who visited the areas
where the clinics would be held two to four weeks before the event took place.
Promotoras encouraged local women to participate in VIA screening. All women 21-65
years old denying pregnancy, presenting for and consenting to VIA testing were
examined.
VIA Methodology and Specimen Collection
Guatemalan nurses who were undertaking the exam, both native Spanish
speakers, obtained consent for the VIA screening. The nurses performing the exam had
been trained during a governmental health department program and subsequently were
hired by Partners for Surgery. Promotoras fluent in Q’eqchi and Mamean languages, the
principal Mayan languages spoken in the region, translated for participants who were
non-Spanish speakers. A separate consent for an additional sample for hrHPV nucleic
acid testing used the form for a research study conducted by the National Cancer
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Institute, National Institutes of Health (NIH). VIA was performed during a speculum
exam to visualize the cervix just after collection of the specimen for hrHPV detection; a
3%-5% dilution of acetic acid (vinegar) was applied to the cervix, which was not a
painful procedure. Visualization of the squamocolumnar junction in the cervix, where
multi-layer tissue composed of squamous cells joins one-layer columnar tissue, was
required for interpretation of VIA. Abnormal precancerous tissue and HPV-related
lesions were expected to become white in appearance when exposed to vinegar, the
principle on which VIA is based35. Specimen collection for HPV subtype determination
with hrHPV testing was done prior to vinegar application during the same speculum
exam with a Dacron swab.
High-Risk HPV Subtype Detection
The specimen was stored in a transport solution until shipment to the NIH
laboratory without refrigeration, where hrHPV testing was done using the Hybrid Capture
2 assay (HC2; Qiagen, Germantown, MD) to detect hrHPV nucleic acid. This testing
characterized HPV subtypes collected during the 2013 screening clinic in Rabinal,
including hrHPV subtypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 with the
kit, and additional subtypes detected in the NIH laboratory including subtypes 32, 67, 81,
and 114. For samples collected in 2013 from other villages, hrHPV positive results were
characterized as such without further subtype characterization. For samples collected
during the 2017 screening clinics, Cobas HPV 4800 Amplification/Detection Kit (Roche
Molecular Systems, Branchburg, NJ) to detect hrHPV including 16 and 18, and 12 pooled
hrHPV subtypes (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). These were performed
at the Palm Beach Pathology Laboratory (West Palm Beach, FL).
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Treatment and Management of Women With Abnormal hrHPV and Results
Cryotherapy was used according to ministry of health guidelines for lesions
believed to be benign but precancerous, but a Partner for Surgery staff member referred
each woman for care in the case of an exam revealing physical changes suspicious for
cervical cancer. The woman was advised regarding the disease, the urgency for treatment
and the facilities that provide such care in the capital, Guatemala City, or local private
care. Demographic data, VIA results and previous cervical screening history and results
data were labeled with a patient identification number linked to the specimen
identification for HPV subtype test, but was unlinked to any other patient identifiers.
These de-identified anonymized data were forwarded to Florida International University
investigators for analysis.
In the 2013 clinics, there was no protocol for advising Partners in Surgery staff
about hrHPV results or for confirming that the women referred actually attended
specialized care. In the 2017 clinic, cytology results were provided to Partners in Surgery
staff so that Promotoras de Salud could advise the women with abnormal results of the
need to seek specialized care, and where to seek such care for sliding scale or reduced
prices.
Statistical Analysis
Data were entered into Excel files and analyzed using Epi Info for Windows
Version 3.5.4 (Centers for Disease Control and Prevention, 2012, Atlanta, GA).
Prevalence ratios (PRs) were used as estimates of relative risk when assessing the
strength of associations; 95% confidence intervals (95%CIs) were used to assess
precision of estimates and for statistical significance testing in bivariate analysis.
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Medians were used as measures of central tendency for continuous variables, and the
Kruskal-Wallis test for two groups, which has no assumption of normal distribution, was
used for statistical significance testing. For analyses of categorical variables, the Χ was
2

used if all expected cells>5; otherwise, Fisher exact two-tailed test was used. Sensitivity
of VIA relative to hrHPV testing was calculated as the proportion of hrHPV positive tests
for which VIA was abnormal, and specificity, as the proportion of hrHPV negative tests
for which VIA was abnormal36.
Results
Human Participant Ethical Review
The Florida International University Institutional Review Board reviewed the
research and considered it a secondary analysis of de-identified data (not human
participant research).
Population
Although 439 women consented to both tests, VIA results were available for only
413 women (189 in 2013 and 224 in 2017) and hrHPV results, only for 394 (170 in 2013
and 224 in 2017); results for both VIA and hrHPV results were available for 393. Most
(76%) were aged 30 years or older (median=36 years; interquartile range [IQR]=30-43
years); 104 (62.3%) reported at least one prior cervical cancer cytological screening with
a Papanicolaou (“pap smear”) test. Just over half were interviewed in Mayan languages
(over 80% of those in Q’eqchi). Almost half were interviewed in Spanish.
VIA and hrHPV Results
Of the women with both VIA and hrHPV subtype test results, 23 (5.9%;
95%CI=3.8%-8.8%) had abnormal VIA; 89 (22.6%; 95%CI=18.7%-27.2%) had nucleic
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acid from at least one hrHPV subtype detected; 65.1% of women with hrHPV subtype
infection were aged over 29 years, ranging from 30-58. Proportions of VIA exams that
were abnormal did not differ significantly by year (7.2% in 2013, 4.9% in 2017), but
hrHPV prevalence varied significantly by year (50 of 169 [29.6%] in 2013, 39 of 224
[17.4%], 2017; P=.004). Of these 89 with hrHPV, 37 were reported with specific
subtypes, of which 26 (70.3%) were HPV16, 1 (2.7%) was mixed HPV16/18, and 2
(5.4%) were HPV18 (Figure 6). HPV16 was less common in 2013 (12/20 [60%]) than in
2017 (15/17 [88.2%]; P=.054).
Sensitivity of VIA for detection of hrHPV in 2013 and 2017 were almost identical
at about only 10.0% (Table 2). The association between abnormal VIA and hrHPV
detection was higher in 2017 than in 2013. In all combined, patients with abnormal VIA
were about 1.8 times as likely to have hrHPV nucleic acid detected than patients who had
normal VIA (P=.05). VIA specificity was 95.4%, with normal VIAs in over 95% of
patients without hrHPV infection. VIA predictive positive and negative values for hrHPV
were 39.1% and 78.4%. In the 2017 screening, one woman aged 47 years who had had
cryotherapy three years before had a cervical tumor visible without magnification or
acetic acid.
Discussion
Indigenous women in six rural villages in Guatemala had a moderately high
prevalence of cervical hrHPV infection. Typing of subtypes among hrHPV-infected
women was only done in about a third; distribution of subtypes differed somewhat by
year. In 2017, using an assay that does not detect some of the subtypes reported in 2013,
the prevalence was lower, with a higher proportion of infections due to HPV16 and 18
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and lower proportion due to “pooled” subtypes. As a result, HPV 16, 18 and 31
contributed to relatively low proportions of infections. However, when restricted to
results from villages for which hrHPV samples were typed, about 70% of infections were
due to subtypes most likely to cause persistent infection and progress to cancer16,36.
Untreated, many hrHPV infections spontaneously resolve, especially those in
women less than 30 years of age37, who usually are recently infected. However, almost
two thirds of our participants with hrHPV cervical infection were over 29 years of age in
our study. Conversely, HPV 16 is associated with more rapid progression and younger
cancer onset2. Even among women with less aggressive subtypes, in this population,
where marriage occurs early in life, and parity is high, hrHPV infections in young women
may be more likely to represent persistent, progressive processes heralding malignancy.
Cyrotherapy has been largely abandoned in high-income countries because it has
not been proven to completely remove abnormal tissue, and is considered of less value in
treating abnormal cells within the cervical canal. Cryotherapy, without excluding cervical
canal abnormalities – an area not evaluated during VIA – may not reduce risk for
persistent infection. Cryotherapy can affect the transformation zone where chronic
infection occurs, preventing adequate screening without colposcopy and endocervical
canal biopsy and is of dubious value in post-menopausal women whose transformation
zone migrates deeper in the os. Our data are insufficient to comment on the value of
cryotherapy, which has been shown to increase regression to normal histology38.
Limitations of this study include use of different assays for hrHPV detection,
likely related to the narrower range of subtypes detected and lower proportion of tests
positive in 2017. Conversely, lack of additional evidence of precancerous or cancerous
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lesions in women tested in 2013 with hrHPV (because no tests, such as cytology, were
done) leaves uncertain how many of these infections may have been clinically
unimportant. Except for the one woman with cervical cancer after cryotherapy, no
information was available on outcomes. Despite these limitations, our study suggests that
in this underserved population, hrHPV-based test-and-treat, without VIA and even
cytology, may be the most cost-effective strategy to reduce cervical cancer burden39-41.
Coupled with scale-up of HPV immunization, hrHPV test-and-treat may reduce the toll
that cervical cancer continues to exact in these underserved women.
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Figure 5. Villages in which visual inspection with acetic acid screening clinics were held
2013 and 2017.
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Figure 6. Distribution (proportions) of high-risk (HR) human papillomavirus (HPV)
results by subtype, 2013 (50 of 169 specimens collected) and in 2017 (39 of 224
specimens collected), Alta and Baja Vera Paz, Guatemala.
NOTE: In 2013, subtypes were only reported on specimens from one village (Rabinal),
with all positive tests from other villages characterized as “pooled” high-risk subtypes. In
2017, assay did not detect some subtypes, but HPV16 and HPV18 were reported from all
villages.

61

Table 2
Sensitivity and Specificity of Visual Inspection With Acetic Acid (VIA) for Detection of
hrHPV, Alta and Baja Vera Paz, Guatemala, 2013 and 2017, and 95% Confidence
Intervals (95%CIs) and VIA Predictive Positive and Negative Values
Sensitivity, Specificity, Predictive Values of Positive and Negative VIA Tests

Sensitivity
Specificity
Predictive

2013

2017

Total

5/50 (10.0%)

4/39 (10.3%)

9/89 (10.1%)

95%CI=3.3%-21.8%

95% CI= 4.7% 18.3%

112/119 (94.1%)

95%CI=2.9% 24.2%
178/185 (96.2%)

95%CI=88.3%-97.6%

95%CI=92.4%-98.5%

95%CI=92.2%-97.4%

5/12 (41.7%)

4/11 (36.4%)

9/23 (39.1%)

112/15 (71.3%)

178.213 (83.6%)

290/370 (78.4%)

290/304 (95.4%)

Value of
Positive
Predictive
Value of
Negative
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Table 3
Association Between VIA and hrHPV Subtype Test Results in 2013, 2017 and Both Years
Combined

2013 Abnormal VIA

hrHPV

Prevalence Ratio

Prevalence

(95% CI)

5/12 (41.7%)

1.45

P
.42

(0.71-2.97)
2013 Normal VIA
2017 Abnormal VIA

45/157 (28.7%)
4/11 (36.4%)

2.21

.20

(0.96- 5.12)
2017 Normal VIA
Total Abnormal VIA

35/213 (16.4%)
9/23 (39.1%)

1.81
(1.05-3.1224)

Total Normal VIA

80/370 (21.6%)
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.05
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Abstract
OBJECTIVE: This study compared the performance of visual inspection with acetic
acid (VIA) within a screen-and-treat approach to oncogenic (high risk) human
papillomavirus (hrHPV) testing relative to a “gold standard” of liquid-based thin-layer
preparation for cytological cervical cancer screening examination in rural indigenous
communities in Guatemala.
METHODS: During six days in September 2017, trained nurses screened 224 women
aged 23-58 years for cervical cancer with VIA. Specimens for cytology and hrHPV
subtype testing were obtained from the cervix prior to VIA with spatula and cytobrush,
and placed immediately into PreservCyt, a methanol-based transport solution. Sensitivity
of VIA and HPV subtype testing were evaluated as proportions of women with abnormal
cytology (excluding abnormal squamous cells of undetermined significance) that had
abnormal VIA or hrHPV subtype test results. Specificity was assessed as proportion of
women with normal cytology that had normal VIA and no hrHPV subtypes.
RESULTS: Of 224 women tested, 221 had usable cytology specimens; of those, 10
(4.7%; 95% confidence interval [CI]=2.3%-8.5%) had abnormal results, including one
carcinoma and four high-grade and five low-grade squamous intraepithelial lesions.
Eleven of 224 (4.9%; 95%CI=2.5%-8.6%) had abnormal VIA and 39 (17.4%;
95%CI=12.6%-23.6%) had hrHPV subtypes detected. Sensitivity of VIA in identifying
precancerous and cancerous lesions was 20.0% (95%CI=2.5%-55.6%); specificity was
96.1% (95%CI=92.4%-98.3%). Sensitivity and specificity of hrHPV-subtype testing in
identifying precancerous and cancerous lesions were 100% (95%CI=71.7%-100%) and
88.7% (95%CI=83.9%-92.7%) respectively. A confirmed cancerous lesion was seen
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using VIA in a patient who had had VIA and cryotherapy four years before. Positive and
negative predictive values were 20.0% and 96.1%, and 30.3% and 100% for VIA and
hrHPV testing respectively.
CONCLUSIONS: VIA-based screening may not consistently identify all women at
highest risk for cervical cancer. hrHPV subtype test-and-treat strategies, usable in the
field in low-resource settings, may be preferable to VIA-based testing.
Introduction
Cervical cancer incidence and mortality decline in high-income countries
accompanied use of cytological screening1 but effective screening strategies in low- and
middle-income countries (LMICs) remain elusive. Oncogenic “high-risk” human
papillomavirus (hrHPV) subtypes cause most cases of cervical cancer, one of the bestunderstood and preventable malignancies, and are present in 95%-100% of cervical
cancer specimens2. Latin American and the Caribbean (LAC), home to just nine percent
of the world population, bear approximately 16% of the world burden of cervical cancer
mortality3. Lack of infrastructure for screening and treatment, particularly in remote rural
populations, are important barriers to detection and treatment. Cervical cancer is believed
to be the leading cause of cancer mortality among Guatemalan women aged 15-44 years4.
In LMICs lacking consistent access to cervical cytology, including in LAC, visual
inspection with acetic acid (VIA) with onsite cryotherapy have been widely adopted5.
Significant challenges in training and implementation of VIA in Guatemala, accompanied
by low reliability and acceptability, may have impacted public sector VIA screening
coverage, which is estimated at 12% to 18%, augmented by non-governmental
organizations to almost 40%6,7. VIA requires minimal equipment: acetic acid (diluted
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vinegar, 3-5%), a light source and speculums to perform the exam. Although VIA does
not allow examiners to “grade” lesions, examiners can treat visible acetowhite lesions
with cryotherapy (ablation with liquid nitrogen) eliminating the need for multiple visits.
The analysis described in this paper compared the performance of VIA to hrHPV subtype
testing, relative to “gold standard” liquid-based thin-layer preparation cytology in rural
indigenous communities in Guatemala.
Methods
Population
Women living in four rural majority indigenous communities (Rabinal, Tactic,
Compur and Cahabon), villages in Alta and Baja Vera Paz, Guatemala, were invited to
attend a VIA clinic at no cost by Partners for Surgery, a non-governmental organization
which provides health services in rural villages including cervical cancer screening to
women aged over 21 years. Local community health promotors employed by Partners for
Surgery informed community members 14-21 days prior to the event.
Design
Cross-sectional analysis of de-identified data collected during brief interviews of
participants, and by VIA, cytological examination and HPV testing.
Setting
Examinations took place in local health centers that allowed privacy for women to
be interviewed assisted by bilingual Spanish-Mayan language interpreters, and examined
by Guatemalan registered nurses trained in VIA. As women consented, a number was
assigned to the cytology and hrHPV specimens and recorded on the VIA result form, to
provide patients with results. Data were anonymized before release to researchers.

67

Liquid-Based Thin-Preparation Cytology and hrHPV Subtype Testing
Specimens for cytology and hrHPV subtype testing were obtained from the
cervix prior to VIA with a spatula and cytobrush, and placed immediately into
PreservCyt, a methanol-based transport solution. Cytology using Thin Prep (Quest
Diagnostics, Alameda, CA) and hrHPV nucleic acid amplification using the Cobas HPV
4800 Amplification/Detection Kit (Roche Molecular Systems, Branchburg, NJ) to detect
14 hrHPV subtypes including 16, 18, 45, and 51 were performed at the Palm Beach
Pathology Laboratory (West Palm Beach, FL). All results were provided to Partners for
Surgery to distribute to patients. Women with abnormal cytology results were referred for
diagnostic evaluation. Those with normal cytology and positive hrHPV testing were
advised to have annual VIA.
VIA and Cryotherapy
A sterile disposable clear plastic vaginal speculum was inserted in the vagina and
freshly prepared 4% acetic acid was applied to the cervix. After one minute, the cervix
was inspected using a hand-held flashlight. If the squamocolumnar junction was
visualized, VIA was considered adequate. VIA was considered positive when a welldefined, dense whitened area with regular margins was visible at the squamocolumnar
junction or the transformation zone. It was considered negative if the squamocolumnar
junction was visualized but no acetowhite lesions5 were observed. Cryotherapy (ablation
with liquid nitrogen) was offered to women with acetowhite lesions. Women whose VIA
examination suggested malignancy (raised, irregular acetowhite lesion, bleeding on
contact) were referred to specialized care on the day of examination with VIA results and
directions to government facilities that offer subsidized care.

68

Data Analysis
Results from the liquid-based thin-layer preparation cytology were considered the
“gold standard” to calculate sensitivity and specificity of VIA and hrHPV. Results with
atypical squamous cells of unknown significance (ASCUS) were excluded from the
analysis. VIA and hrHPV subtype test sensitivities were calculated as proportions of
women with abnormal cytology specimens whose VIA or HPV test was abnormal or
positive, respectively. Specificities for VIA and hrHPV testing were calculated as
proportions of women with normal cytology specimens with normal VIA or hrHPV
results. Prevalence of abnormal VIA exams and hrHPV tests among women with
abnormal cytological examinations (excluding ASCUS with negative HPV) was
compared to prevalence in women with normal cytological examinations. Prevalence
ratios were used as estimates of relative risk; 95% confidence intervals (95%CIs) were
used to assess precision of estimates, and along with Fisher exact two-tailed tests, for
statistical significance testing. All analyses were performed with Epi Info v. 3.5.4
(Centers for Disease Control and Prevention, Atlanta, GA).
Human Participant Ethical Review
The Florida International University Institutional Review Board reviewed the
research and considered it a secondary analysis of de-identified data (not human
participant research).
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Results
Nurses screened 224 women aged 23-58 (median age=36; interquartile range=3043) years. Three (1.3%) had insufficient cells to perform liquid-based thin preparation
cytological testing. Of the 221 with usable cytological specimens, 10 (4.7%; 95%CI:
2.3%-8.5%) had abnormalities, including a carcinoma in a woman who had had VIA and
cryotherapy in 2015, and five low-grade and four high-grade intraepithelial lesions
(excluding eight with ASCUS). Among those 10, seven had had at least one previous
VIA examination. Eleven (4.9%; 95%CI: 2.5%-8.7%) of the VIA examinations were
abnormal, including the carcinoma. Five of the 11 with abnormal VIA, including the one
with the lesion, were referred to specialized care, and four cryotherapy treatments were
administered; two others were asked to return for cryotherapy but did not do so. Fiftyeight (25.9%) women had never had a pelvic exam; median age of women without a prior
pelvic exam was 33 years (vs. 38 years in others; p=0.001).
hrHPV subtypes were detected in 39 (17.4%; 95%CI: 12.7%-23.0%) women.
hrHPV subtype testing detected all 10 (sensitivity=100%; 95%CI: 71.7%-100%) women
with abnormal cytological examinations. VIA detected only 2 of 10 (sensitivity=20%;
95%CI: 2.5%-55.6%). Specificities of hrHPV subtype testing and VIA were 181/205
(88.7%; 95%CI: 83.9% 92.7%) and 194/202 (96.1%; 95%CI=92.4%-98.3%),
respectively. Median ages and numbers of children of women with and without VIA
abnormalities or hrHPV subtypes, did not differ significantly (data not shown).
Both abnormal VIA and positive hrHPV tests were associated with abnormal
cytological results, but association with positive hrHPV tests was stronger and
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statistically significant (Table 4). Positive and negative predictive values were 30.3% and
100% for hrHPV testing and 20.0% and 96.1% for VIA. Cryotherapy was used to treat
four women with abnormal VIA who did not have abnormal cytology or hrHPV.
Discussion
In this small study, VIA and hrHPV subtype testing had very different
sensitivities (20% vs. 100%) relative to cytology. Of the two women with abnormal VIA
and cytological examinations, one had had an abnormal VIA and cryotherapy before, and
presented with a cancerous lesion. These findings suggest that the sensitivity of VIA for
cervical cancer screening conducted by highly trained nurses in this setting may be low
compared to hrHPV testing, and that VIA-guided cryotherapy may not always affect the
course of precancerous lesions. VIA may not be as reliable in menopausal women, and
hrHPV testing in younger women, but in this study, age did not affect either. hrHPV
prevalence in Guatemala sex workers at STI clinics and in women at community health
centers was 67.3% and 38.1% respectively8, higher than observed in our study population
(17.0%), in which no variance was seen by age or parity, (which has been associated with
higher persistence of hrHPV).
This study had several limitations. Because abnormal cytology prevalence was
low (4.7%), precision of sensitivity and hrHPV positive predictive values were low. The
use of cytological testing as a “gold standard” may underestimate hrHPV testing
specificity, since hrHPV persistence may precede cytological evidence of precancerous
changes. The study did not confirm abnormalities with biopsy, requiring ASCUS
exclusion. The screening was offered in only four communities. Many women traveled
hours by foot to attend, suggesting that women screened may have been more interested
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in screening than the general rural Maya population, and may not reflect population-level
risk.
Nevertheless, our study suggests that VIA-based screening may miss women with
treatable precancerous lesions and points to the promise of point-of-care real-time nucleic
acid hrHPV testing, concurring with the World Health Organization recommendation to
use a strategy of ‘screen with an HPV test and treat’, over a strategy of ‘screen with VIA
and treat’9. In rural India, this approach decreased advanced cervical cancer and related
deaths by over 40%, without significant reductions using cytological or VIA-based
screening in comparison groups10. Cervical cancer is an important cause of death in
Guatemala. Our findings suggest concerns with use of VIA alone for cervical cancer
screening.
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Table 4
Associations Between Abnormal Visual Inspection With Acetic Acid (VIA) and Cervical
Cytological Results, and Between Oncogenic (High-Risk) Human Papillomavirus
(hrHPV) Results and Cervical Cytological Results, Excluding Samples With Atypical
Cells of Unknown Significance (ASCUS)
Screening Test Results for
VIA and hrHPV Subtype
Testing

Number (%) positive in
women with abnormal
cervical cytological
results

Prevalence
Ratio
(95%CI)*

Fisher
Exact
2-tailed
p-value

Abnormal

2/ 10 (20.0)

5.1 (1.2-21.0)

0.145

Normal

8/203 (3.9)

Positive

10/33 (30.3)

----†

<0.0001

Negative

0/180 (0) †

----

VIA Results

hrHPV Test Results

*95% confidence interval; †Denominator=0 (no false positives); undefined, cannot divide
by 0
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Abstract
OBJECTIVE: To determine prevalence of cervical infection with oncogenic (“highrisk” [hr]) human papillomavirus (HPV) in indigenous women participating in two visual
inspection with acetic acid (VIA) cervical cancer screening events and identify factors
associated with hrHPV cervical infection in participants.
METHODS: De-identified Data collected by interview and assays during VIA cervical
cancer screening events in 2013 (N=205) and 2017 (N=234) for indigenous women aged
21-65 years in six villages in Guatemala. Cervical specimens were collected for nucleic
acid amplification testing to detect hrHPV before VIA was conducted.
RESULTS: Of 394 women with hrHPV results, 90 (22.8%) had nucleic acid from at
least one hrHPV subtype detected, 48.3% of whom had infection with subtypes 16 or 18,
the subtypes most likely to be associated with persistent infection and cancers. Women
aged less than 29 years or reporting less than four pregnancies were more likely to have
hrHPV cervical infection (36.8%, 27.3%, respectively) than those who were older or
reported more pregnancies (18.7; <.0001 and 17.9%; P=.025, respectively). Women who
reported use of progesterone injections or implants were more likely to have hrHPV
detected (31.9%) than those who used other or no contraception (19.5%; P=.013). When
controlled for other factors in logistic regression, younger age, lower parity, progesterone
injection or implant use, or examination in 2013, were independently associated with
hrHPV infection.
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CONCLUSION: The association of hrHPV infection with long-acting progesterone
contraceptive use may reflect progesterone’s action as a co-factor promoting hrHPV
persistence.
Introduction
Persistent cervical infection with several subtypes of human papillomavirus
(HPV), (oncogenic or “high risk” [hr] HPV subtypes), have been recognized since the
1980s to be necessary for the development of cervical cancer1. However, infection alone
with hrHPV subtypes does not appear to be sufficient to cause progression to cervical
cancer. Several “cofactors” for the development of cervical cancer have been identified,
including low literacy, multi-parity, and history of sexual abuse, older age, low
socioeconomic status, and in some cases, racial and ethnic minority group status2.
Screening tests that detect lesions before they progress to cancer, a process that for
women with normal cell-mediated immunity, can take years or even decades, can arrest
the process1,2. As such, many of the demographic and socioeconomic “cofactors” appear
to reflect lower access to health care and preventive services, when controlled for hrHPV,
cervical cancer screening and linkage to specialized care2. Lower access in Guatemalan
indigenous women is related to language barriers, since many indigenous women do not
speak Spanish, the national language, but rather, indigenous, mostly Mayan languages,
and to very high rates of poverty (with over 70% of indigenous people, over half of
Guatemala’s population living in severe poverty)3,4. Disenfranchisement and
marginalization of Guatemalan indigenous groups has coincided with much worse health
outcomes than counterparts of European descent5.
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Biological factors have been investigated in other settings, particularly links to
hormonal contraception, but their role in high-parity marginalized populations, believed
to have less hormonal contraception exposure, remains less studied. The objective of this
analysis was to estimate prevalence of cervical infection with hrHPV subtypes in
indigenous women participating in visual inspection with acetic acid (VIA) cervical
cancer screening activities in 2013 and 2017, and identify factors associated with hrHPV
in participants.
Methods
VIA Screening Clinics
Six villages were visited in two weeks in 2013 and in 2017, including in Baja
Vera Paz, north of the capital region, and Alta Vera Paz, north of Baja Vera Paz. Rabinal
and Campur were each visited in both 2013 and 2017. Cahabon and Santa Cruz were
visited only in 2013 and Canchar and Tactic, in 2017 only. The VIA screening clinics
were supported by two NGOs that collaborate to bring services to rural Guatemala
(Partner for Surgery and Timmy Global Health in 2013, Partner for Surgery in 2017). The
VIA screening clinic schedule was coordinated with the local communities to arrange for
space to provide the clinic. Availability of cervical cancer screening and time and date
were announced by Promotoras de Salud (female Community Health Promoters)
employed by Partners for Surgery, who visited the areas where the clinics would be held
two to four weeks before the event. Promotoras encouraged local women to participate in
VIA screening. All non-pregnant women 21-65 years of age who attended the events and
consented to VIA were examined. Women had a brief interview to obtain basic
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information (e.g., age, parity, previous cervical cancer screening and treatment,
contraception).
VIA Methodology and Specimen Collection
Nurses who performed the exam obtained consent for the VIA screening.
Promotoras fluent in the principal Mayan languages spoken in the region, translated for
participants who were not Spanish speakers. A separate consent for an additional sample
for HPV nucleic acid amplification testing used the form for a research study conducted
by the National Cancer Institute, National Institutes of Health (NIH) in 2013. In 2017, a
separate consent sought an additional sample for HPV nucleic acid amplification testing
and for cytological testing. VIA was performed during a speculum exam to visualize the
cervix just after collection of the specimen for hrHPV detection; a 3%-5% dilution of
acetic acid (vinegar) was applied to the cervix. Visualization of the squamocolumnar
junction in the cervix, where multi-layer tissue composed of squamous cells joins onelayer columnar tissue, was required for interpretation of VIA. Abnormal precancerous
tissue and HPV-related lesions were expected to become white in appearance when
exposed to vinegar, the principle on which VIA is based.6 Specimen collection for HPV
subtype determination in 2013 and 2017, and in 2017, cytology sample, were obtained
prior to vinegar application during the same speculum exam with a Dacron swab.
High-Risk HPV Subtype Detection
In 2013, the specimen was stored in a transport solution until shipment to the NIH
laboratory without refrigeration, where hrHPV testing used the Hybrid Capture 2 assay
(HC2; Qiagen, Germantown, MD) to detect hrHPV nucleic acid. This testing
characterized hrHPV subtypes 16, 18 and 11 “pooled” subtypes 31, 33, 35, 39, 45, 51, 52,
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56, 58, 59, and 68; additional subtypes detected in the NIH laboratory included 32, 67,
81, and 114 for specimens collected in Rabinal in 2013. For other villages in 2013, no
breakdown of hrHPV subtypes was provided. For samples collected in 2017, Cobas HPV
4800 Amplification/ Detection Kit (Roche Molecular Systems, Branchburg, NJ) was used
to detect hrHPV including 16 and 18, and 12 pooled hrHPV subtypes (31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 66 and 68) at the Palm Beach Pathology Laboratory (West Palm
Beach, FL).
Treatment and Management of Women With Abnormal hrHPV and Results
Cryotherapy was used according to ministry of health guidelines for lesions
believed to be benign but precancerous. Partner for Surgery staff members referred
women for care in the case of an exam revealing physical changes suspicious for cervical
cancer. Women were advised regarding the disease, the urgency for treatment and the
facilities that provide such care in
the capital, Guatemala City, or local private care. Demographic and interview data, VIA
results and previous cervical screening history were labeled with a patient identification
number linked to the specimen identification for HPV subtype test (and cytology result in
2017), but were unlinked to any patient identifiers.
In the 2013 events, there was no protocol for advising Partners in Surgery staff
about hrHPV results or for confirming that the women referred actually attended
specialized care. In the 2017 events, cytology results were provided to Partners in
Surgery staff so that Promotoras de Salud could advise the women with abnormal results
of the need to seek specialized care, and where to seek such care for sliding scale or
reduced prices.
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Statistical Analysis
Data were entered into Excel files and analyzed using Epi Info for Windows
Version 3.5.4 (Centers for Disease Control and Prevention, 2012, Atlanta, GA).
Prevalence ratios (PRs) were used as estimates of relative risk when assessing the
strength of associations between putative predictors and hrHPV infection; 95%
confidence intervals (95%CIs) were used to assess precision of estimates and for
statistical significance testing in bivariate analysis. The Kruskal-Wallis test for two
groups, which has no assumption of normal distribution, was used for statistical
significance testing for continuous variables. For statistical significance testing of
categorical variables, the Χ was used if all expected cells >5; otherwise, Fisher exact
2

two-tailed test was used.
Human Participant Ethical Review
The Florida International University Institutional Review Board reviewed the
research and considered the analysis of de-identified anonymized data forwarded to
Florida International University investigators for analysis not human participant research.
Results
As was typical for this type of event, hundreds of women (N=205), and N=234 in
2017; total N=439) attended the VIA clinics. Many came on foot from villages miles
away, and waited up to 7-8 hours for screening. hrHPV results were available from 170
women examined in 2013 in Campur, Rabinal, Cahabon and Santa Cruz, and 224 from
women examined in 2017 in Campur, Rabinal, Carchar and Tactic (Total N=394, 89.4%
of attendees); 90 (22.8%) had at least one hrHPV subtype detected. Of 60 positive hrHPV
results from villages where specimens were characterized by subtype (Rabinal in both
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years and Carchar and Tactic in 2017), 29 (48.3%) were subtypes 16 and 18, the subtypes
most likely to be associated with persistent infection and cervical cancer. Women’s ages
ranged from 21 to 59 years (median=36 years; interquartile range [IQR]=30.0-43.0
years). Of 385 who gave information about contraceptive use (167 in 2013, 218 in 2017),
most (234 [60.0%]) used some form of contraception. Data on language used during
interview were available for 214 women of whom 48.1% were interviewed in Spanish.
The proportion of women who reported no contraception was almost identical among
women interviewed in Spanish (35.9%) and among those interviewed in Mayan
languages (38.7%; P=.67). The most frequently reported contraception, used by 91
(23.5%), was long-acting progesterone injection or implant; 86 reported surgical
sterilization and 28 (7.1%), oral contraceptives. Almost 67% reported at least one “Pap”
cytological screening test in the past.
hrHPV prevalence did not vary significantly by village in either year, ranging
from 26.3% in Rabinal to 36.8% in 2013, and from 17.1% in Rabinal to 17.9% in
Canchar, but was significantly higher in 2013 (30.0%) than in 2017 (17.4%); P=.003
(Table 5). Women who were aged less than 29 years or who had had less than four
pregnancies were also more likely to have hrHPV cervical infection. Women who
reported progesterone injection or implant use were more likely to have hrHPV (31.9%)
detected than those who used other or no contraception (19.5%; P=.013). When
controlled for other factors in logistic regression, younger age, examination in2013, and
progesterone implant or injection for contraception were independently associated with
hrHPV co-infection (Table 6).
Discussion
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VIA is often considered a cervical cancer screening option for women with little
or no access to care. Yet the majority of women tested as part of the screening activities
described here reported prior cytological cancer screening and contraception (mostly
prescription or surgical sterilization) use. Since early as the 1960s, as the use of oral
contraceptives increased worldwide, the effect of exogenous steroid hormonal
contraception began to be investigated as a possible co-factor in cervical cancer
development.6 Studies focused on oral combined hormonal contraception, which was
more widely used. Recently, long-acting reversible contraception delivered by implant,
and less conveniently, by quarterly injection) has been promoted in LMICs where health
care access may be difficult7.
The association between hormonal contraception and cervical cancer has been
increasingly investigated as cervical cancer cofactors with mixed results. In contrast,
behavioral factors have lessened in importance as cofactors, since they have been noted
to only modestly increase risk of development of cervical cancer in women testing
positive for hrHPV2. Looking beyond circumstantial risk and into genetic factors both of
the woman and of hrHPV itself, may help elucidate the role of exogenous hormone use.
In 1990, Herrero et al.8 demonstrated the association between long-term injectable
progesterone contraception use and cervical cancer.
Several issues in this analysis limit its generalizability. Like many clinic
populations, rural populations that overcome significant barriers to attend a VIA clinic,
and report prescription contraception and prior cytological examinations, as the
populations described in this report may not represent the most marginalized populations,
but rather, highly motivated individuals who greatly value health care. The possibility of
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recall and social desirability bias is present, as lapses (particularly failure to attend
appointments for injectable progesterone) may be difficult to remember, and long-acting
contraception is energetically promoted to marginalized populations.7 The prevalence of
hrHPV infection was high overall, but much higher in 2013. It is unclear why prevalence
overall declined in 2017, although the higher number of attendees may reflect a change
towards broader representation of lower-risk individuals.
Despite these limitations, this analysis demonstrates an association, independent
of age and parity between long-term progesterone exposure and hrHPV infection, with
higher risk in these users than in women who report not using any contraception and
women using contraception other than progesterone-based methods. Essential to
women’s empowerment is fertility control, of particular importance in countries where
women, particularly women of indigenous background, experience barriers, including
discrimination5, in healthcare access. The long-term delivery systems allow for less need
to access health care and pharmacy, cost and greater privacy in their contraception use.
Beyond the fertility control, progesterone-only products reduce or eliminate menstrual
bleeding, decreasing monthly hygienic challenges and anemia.
Recent studies have been able to describe the natural history of hrHPV infections,
evaluate genetic components of hrHPV subtype persistence, and the effect on the cervical
tissue of hormones such as estrogen and progesterone9,10. The analysis of multi-parity
associated with increased risk for cervical cancer has suggested that high hormonal
milieu effect cervical tissue changes occurring after a birth which result in increased
exposure of the transformation zone where hrHPV infection occurs9,10. Chagas et al.9 in
studying oral contraception and cervical cancer identified a gene polymorphism which, if
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present, increases an oral contraceptive user’s risk for cervical cancer. Additionally, it is
known that estrogen and progesterone stimulate HPV16 expression producing anti-tumor
suppression by E6 and E7 oncogenes.9,10 Improved understanding of genetic interactions
could help better define the risk for cervical cancer through specialized screening for
women interested in use of hormonal contraceptives. Multiparity and hormonal
contraception both increase women’s hormone exposure, endogenous (hormonal support
of pregnancy) and exogenous (contraception), both may increase risk for cervical cancer
by promoting expression of hrHPV, underscoring the importance of accessible
reproductive health care that includes cervical cancer screening for underserved women
in Guatemala.
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Table 5
Characteristic Associated With Statistically Significant Increased Risk of High-Risk (hr)
Human Papillomavirus (HPV) Cervical Infections in Rural Indigenous Women in
Guatemala Attending Visual Inspection With Acetic Acid Cervical Cancer Screening
Clinics
Characteristic

Year, 2013

Number with hrHPV

Prevalence Ratio

Infections/Total Number

(95% Confidence

with Factor (%)

Interval)

51/170 (30.0)

1.72

P-value

.003

1.19-2.49
Year, 2017

39/224 (17.4)

Age less than 29

28/76 (36.8)

1.97

years

(1.35-2.86)

Age 29 or older

59/315 (18.7)

Less than 4

50/133 (27.3)

1.43

pregnancies
4 or more

<.0001

.0253

(1.05-2.23)
37/207 (17.9)

pregnancies
Progesterone

21/91 (31.9)

1.63

Injectable or

(1.12-2.38)

Implant User
Progesterone

58/297 (19.5)

Injectable or
Implant Non-User

87

.013

Table 6
Factors Associated With High-Risk Human Papillomavirus (hrHPV) Cervical Infection
in Logistic Regression, Controlling for Examination in 2013, age Less Than 29 Years,
Parity Less Than Four, and Progesterone Depot and Implant use, Confined to 387
Women Without Missing Values in all Variables

Factor
Age less than 29
years
Progesterone depot or
implant use
Parity less than four
Examination in 2013

Odds Ratio

95%
Confidence
Interval

P-Value

1.92

1.02-3.60

0.0421

1.80

1.04-2.12

0.0361

1.32
1.97

0.76-2.30
1.20-3.23

0.3233
0.0077
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VI: SUMMARY AND DISCUSSION
Summary
These analyses of data collected in the Vera Paz regions of Guatemala provide
insight into the state of cervical cancer screening programs for underserved rural
indigenous women in the region. As previously noted, the health system is reliant upon
NGOs to extend services into the remote areas of the country1. The NGO that conducted
VIA exams is tasked with screening, and aside from onsite, immediate cryotherapy, has
limited avenues to provide or secure further treatment. In 2013, the evaluation of the
VIA exam was a first look at hrHPV prevalence in the Vera Paz region. In 2009 Valles2
reported there were no data available regarding the burden of high-risk (hr) human
papillomavirus (HPV) infection in Guatemala, and the estimated coverage of cytological
testing (with Papanicolaou tests [“pap smears”] or liquid preparations) was less than
10%. Since then, hrHPV prevalence in Guatemalan women in the general and sex
worker populations have been reported as 38.1% and 67.3%, respectively3; 17% of
indigenous women in Santiago de Atitlan, Guatemala, had at least one hrHPV subtype
detected in self-obtained samples4. In evaluating prevalence of hrHPV in the region, six
communities participated in the screening, with a combined prevalence of over 22.8%,
somewhat higher than the estimated prevalence of 16.1% in Latin America and the
Caribbean that Bruni3 et al. reported.
An age-adjusted evaluation by Bruni3 showed a peak in early adulthood, then a
second peak in hrHPV infection in Central and South America at age 45, clearly
emphasizing the need for lifelong screening. The small prevalence study in 2013 also
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compared VIA to the hrHPV findings. Of the women examined during this activity only
eight VIA exams were positive, and of the 42 positive hrHPV, only three of the women
who tested positive had abnormal VIA exams. The 2013 study had unanswered questions.
There was no comparison with cytology or pathology to confirm the presence of
precancerous changes in chronic infections sought in the VIA exam.
Of importance is the setting for examination; the nurses were using hand-held
flashlights with varying light devices and used vinegar stored in equipment cases in the
transport vehicles. Adequate light is required to visualize the changes made by acetic acid
application. Each site used for VIA exams had difficulty providing privacy and women
had to present in the morning, some not being seen until late afternoon.4 Heat exposure5
could affect acetic acid composition, and cause burning and irritation.
In some studies, VIA sensitivity for high-grade cervical intraepithelial neoplasia
(cancerous or very likely precancerous lesions) has ranged from over 50% to over 80%,
varying by menopausal status6,7. However, VIA only detected 20% of cytological high
and low-grade lesions during the 2017 screening activity. The screeners were dedicated
Guatemalan nurses trained in VIA examination, traveling monthly to rural areas of
Guatemala to provide screening. They work in difficult conditions, in clinics that often do
not have running water, or adequate exam tables. In the 2017 study, 17.0% of women
presenting for VIA had positive nucleic acid amplification tests hrHPV. VIA had a
sensitivity of 20% in identifying abnormal cytological findings (excluding atypical cells
of unknown significance). In contrast, sensitivity and specificity of hrHPV in detecting
precancerous and cancerous lesions were 100% and 88.6% respectively. In a large recent
study in Tanzania, VIA sensitivity relative to cytological and HPV testing was
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unacceptably low, and varied significantly by screener experience, HIV infection status
and age8.
The VIA screening activities have the capacity to treat women with positive
exams, onsite without requiring a return visit. During the 2017 VIA screening activity
four women were treated with cryotherapy; all of the ones treated had normal cytology
and negative hrHPV. Cryotherapy is recommended onsite to prevent losing women with
positive tests to follow-up, in some LMICs as high as 80% of women with precancerous
lesions do not receive treatment9. Missing the opportunity to treat prior to malignant
disease substantially raises costs financially and in lives lost. Cervical cancer is a disease
that affects women in the middle years of life; Yang et al.10 calculated years of life lost
(YLL) and found in Latin America and the Caribbean region, cervical cancer YLL
represent a larger contribution than tuberculosis, maternal conditions or AIDS. However,
none of the cryotherapy treatments were provided to women with evidence of
precancerous lesions or persistent hrHPV infection.
The data suggest that the prevalence of hrHPV infection is high in this region of
Guatemala, where access to screening programs is dependent upon mobile units
supported by NGOs working independently or contracted by the Ministry of Health1.
Poor indigenous women have high risk for cervical cancer primarily due to lack of
screening resources, but also in the socio-demographic milieu of marginalization and
isolation. Their high fertility rates have been established to contribute possible as a cofactor in risk in cervical cancer11. This region is one of the poorest in Guatemala, with
limited road system; Owen12 in 2009 analyzed Alta Vera Paz and found the total network
consisted of 4.1% paved roads, 31.3% unpaved roads with 64.5% identified as trails. This
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clearly demonstrates the remoteness of the area. Long identified barriers to cancer
screening and treatment include rural residency, poverty and being uninsured13,14
characteristics shared by many indigenous women in Guatemala in this region. In 2006 a
qualitative study in Rabinal, Baja Vera Paz, one of the six communities participating in
the VIA screening in 2013 and 2017, identified language and transportation as barriers to
care, and noted that traditionally women first consult their husbands for their own health
care and health care of the children15. These practices delay care and demonstrate the
importance of education and community support of VIA screening. Empowering women
by increasing their independent access to screening, and identifying and addressing
beliefs that serve as a barrier to screening will help to provide acceptable screening in the
community. Research has found the importance of involving the community in
partnership for developing acceptable strategies16 to involve women in screening and also
understanding the recommendation for continued surveillance for life. Moreover, in
general, women (particularly in crowded settings with low privacy), like indigenous
women in Atitlan, Guatemala, prefer self-obtained noninvasive specimen collection4
Screening will require more reliable strategies than VIA. VIA in this study fell
short of expectations, but could be significantly enhanced or replaced with hrHPV
subtype real-time testing onsite17. Self-sampling acceptability has been investigated in a
small indigenous community in Guatemala and in other communities worldwide4,18. The
authors determined that women preferred the self-sampling to an exam by physician, with
95% of the indigenous participants completing the study. Findings in the New Delhi
study suggested that “self-HPV sampling compares favorably with physician-sampling
and cytology. Rapid, affordable, HPV self-test kit can be used as the primary method
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of cervical cancer screening in low-resource situations18. These studies offer a sampling
method preferable to the pelvic exam in this indigenous community. Reserving VIA, pap
and colposcopy for women identified as high risk due to hrHPV infection would conserve
resources. A rapid, affordable, HPV self-test kit can be used as the primary method of
cervical cancer screening in low-resource situations.
Theory of Planned Behavior
Some of the findings of the studies in this dissertation stand in contrast to the
hypotheses, and even to the basic understanding of the cultural and social barriers to
accessing women’s health care, but they are amenable to explanation by the Theory of
Planned Behavior. Although most women chose to be interviewed in their community’s
Mayan language, suggesting low acculturation, many of the cultural barriers assumed to
occur in these communities were not identified. The majority of women accessing VIA
reported previous cytological evaluation. Most (60.0%) reported contraceptive use.
Clearly, their attendance at an event requiring hours of walking to arrive in the early
morning and hours of waiting to be seen suggests that this group utilizes and values
women’s health services. In fact, the proportion of VIA clinic participants who reported
modern contraceptive method use was substantially higher than the proportion of married
women at the national level reporting modern contraceptive use in the population-based
2015 Guatemala Demographic and Health Survey (48.9%)19. It was also far higher than
the proportion reported in a recent study of contraceptive use by women living in poverty
in five Central American countries for Guatemala (27.5%)20. In that study, Guatemala’s
poorest women had the second lowest level of contraceptive use of the five countries
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assessed, which ranged from 15.3% in Panama to 82.2% in Nicaragua. This same study
identified indigenous ethnicity as a strong predictor of failure to use modern
contraceptive methods.

In comparing the women attending the 2013 and 2017 VIA clinics to the women
described in those reports, the Theory of Planned Behavior is instructive (Figure 2). The
work of community health promoters is the first step towards creating attitudes consistent
with accepting cervical cancer screening. Their visible participation in recruitment,
organizing and implementation of the activity normalizes the exam, and the numbers of
women that attend each VIA clinic further reinforce the attitude that this is a valuable and
desirable service. As dozens of neighbors of all ages attend the activities, the subjective
norm shifts to acceptance by the community, including by male partners, of the need for
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an intrusive examination to preserve health and prevent deaths of wives and mothers.
Finally, the ownership of the activity by the community, familiarity of the setting, service
availability at no cost, and presence of community translators and facilitators affirms
women’s perceived behavior control, in a setting of considerable peer support.
This process, which begins with understanding screening and acceptance by the
community allows women to seek screening for cervical cancer by intention21 and
participation in a community-screening event, has women supporting each other.
However, this activity is only as successful in prevention of cervical cancer as the
efficacy of the screening method, and the linkage to effective care for women found to
have precancerous or cancerous lesions. Identifying appropriate screening schedules and
more reliable, cost-effective methods is a first step in adequate surveillance and improved
estimates of cervical cancer incidence and mortality in indigenous populations and is vital
to reducing the mortality associated with cervical cancer in this population. Screening
ages have been evaluated for the greatest lifetime risk for cervical cancer reduction
potential22. The natural history of hrHPV in immunocompetent women provides for
intermittent screening, and the mean age of women with invasive cervical cancer is 50
years, as estimated by Baseman and Koutsky23. VIA is known to have decreased
sensitivity in older24,25 women, who at higher risk due to age, require a better screening
tool and should be targets of screeners.
Guatemala struggles to provide cervical cancer-screening services to women; in
200826 it was estimated that only 40% of women had ever been screened. Self-HPV
sampling compares favorably with physician sampling and cytology and clearly must be
pursued. However, Chary followed women referred for specialized diagnostic testing and
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treatment for cervical cancer and found that inadequate equipment, equipment in
disrepair and understaffing constrained the system, reporting 1200-1700 patients on a
waiting list for radiation therapy27. The lack of treatment options poses the question of
health ethics: is screening and diagnosis in communities without access to treatment
inconsistent with the aim of screening. The persistent determination is that infrastructure
for screening and linkage to care is poor in many LMICs as in Guatemala. The strategy of
utilizing a proven – not perfect – tool such as cytology may not be attainable at present
for marginalized populations in LMICs but hrHPV testing may be.
Infrastructure development for cancer registries would help define the extent of
the problem, as current incidence and mortality estimates are unreliable28 29 particularly
for indigenous women. Cervical cancer represents 36% of new cancers being treated in
201227 per Instituto de Cancerología (INCAN) patient registry, which also estimates only
one third of patients initiating treatment complete therapy. Very often, the diagnosis of
cervical cancer in members of marginalized populations is in later stages requiring
specialized equipment, surgery and expensive chemotherapy or radiation therapy. This
places considerable strain on the system as well as on families to little gain. Cervical
cancer is predicted to increase by 75% in the region by 202524, threatening a crisis in
indigenous women’s survival.
Root cause analysis of cervical cancer screening problems would center the
discussion on infrastructure, not only to screen, but also to include streamlining linkage
from screening to definitive diagnosis to treatment to cure. Awareness of risk for cervical
cancer and understanding of the natural history of hrHPV infection is paramount to
community and individual adherence with screening recommendations, and should be
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incorporated by the local health promoters working with NGOs. For indigenous women,
language, illiteracy, poverty, discrimination and violence serve to marginalize them
placing these women at higher risk for cervical cancer, the theory of Gender and Power is
a descriptor of circumstance of many Guatemalan women.
Strengths and Limitations
The strength of these studies is that it was a glimpse at hrHPV prevalence in a
previously understudied population. Valles2 reported on prevalence comparing sex
workers to “general population” (non-sex workers) women finding prevalence in women
in the general population group did not decline with age as is expected; another small
study in Atitlan indigenous women showed the acceptability of self-obtained samples.
Comparing VIA to cytology and hrHPV testing had not been done in Guatemalan
indigenous populations prior to this study. VIA has been embraced by the Ministry of
Health and therefore NGOs. While small, the study demonstrated a lower sensitivity than
expected (22.2%) and a specificity of 96%. Conversely, with the strong showing of
hrHPV testing (sensitivity and specificity: 100% and 88.6% respectively), real-time
onsite hrHPV testing with or without VIA, reserving cytology and pathology for women
with chronic hrHPV may save funds, time and staff resources, as a new infrastructure is
established.
Limitations of the study include small sample sizes, with poor precision of
estimates, low numbers of outcomes (e.g., one frank, invasive cancer after cryotherapy,
nine low and high squamous cell ) and confining population to Vera Paz, so that this
study cannot be assumed to represent indigenous women in Guatemala, the largest such
population in Central America. Clearly, the population’s level of commitment to health
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and prevention, use of contraception and cervical cancer screening makes them
unrepresentative. The possibility of recall and social desirability bias when discussing
these issues, where there is a clearly stated priority to engage indigenous women in these
activities, is high.
Conversely, these women, clearly extremely poor, underserved, marginalized
people, prove that community-based screening for cervical cancer can attract them, and
obviously more than once. Even if these women exaggerate their use of contraception and
cervical cancer screening, that exaggeration itself clearly reflects a level of normalization
(Figure 7) that is essential for population-based uptake of screening.
Conclusions
For next steps in promotion of cervical cancer screening (and contraception),
these communities can serve as “early adopters”, partners in diffusion of innovation.
Exploration of indigenous women’s understanding of cervical cancer and their
acceptance of treatment, particularly in absence of significant symptoms, is essential in
developing measures to ensure adherence to screening and treatment recommendations.
Building on Dr Chary’s research on treatment at INCAN, following up with women
referred for specialized diagnostic procedures and treatment from Vera Paz would help
assess the effectiveness of cervical cancer screening.
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